Prognostic value of the 21-Gene Breast Recurrence Score® assay for hormone receptor-positive/human epidermal growth factor 2-negative advanced breast cancer: subanalysis from Japan Breast Cancer Research Group-M07 (FUTURE trial).

Iwamoto T, Niikura N, Watanabe K, Takeshita T, Kikawa Y, Kobayashi K, Iwakuma N, Okamura T, Kobayashi T, Katagiri Y, Kitada M, Tomioka N, Miyoshi Y, Shigematsu H, Miyashita M, Ishiguro H, Masuda N, Saji S

Breast cancer research and treatment   2024.6（ ISSN:0167-6806 ）

Prognostic value of the 21-Gene Breast Recurrence Score® assay for hormone receptor-positive/human epidermal growth factor 2-negative advanced breast cancer: subanalysis from Japan Breast Cancer Research Group-M07 (FUTURE trial).

Iwamoto T, Niikura N, Watanabe K, Takeshita T, Kikawa Y, Kobayashi K, Iwakuma N, Okamura T, Kobayashi T, Katagiri Y, Kitada M, Tomioka N, Miyoshi Y, Shigematsu H, Miyashita M, Ishiguro H, Masuda N, Saji S.

Breast Cancer Res Treat.   2024.6

Impact of immediate breast reconstruction on perioperative therapy: insights from a Japanese Nationwide Registry.

Sasada S, Kumamaru H, Hayashi N, Kinukawa N, Toi M, Jinno H, Saji S.

Breast Cancer.   2024.6

Impact of immediate breast reconstruction on perioperative therapy: insights from a Japanese Nationwide Registry.

Sasada S, Kumamaru H, Hayashi N, Kinukawa N, Toi M, Jinno H, Saji S

Breast cancer (Tokyo, Japan)   2024.6（ ISSN:1340-6868 ）

Association between specific human leukocyte antigen alleles and development of thyroid immune-related adverse event.

Sasaki E, Natori Y, Tokuda E, Kimura-Tsuchiya R, Suga J, Kanazawa K, Koguchi T, Kikuchi N, Okabe N, Murono S, Tachibana K, Soeda S, Shimabukuro M, Saji S.

Immunotherapy.   2024.6

Association between specific human leukocyte antigen alleles and development of thyroid immune-related adverse event.

Sasaki E, Natori Y, Tokuda E, Kimura-Tsuchiya R, Suga J, Kanazawa K, Koguchi T, Kikuchi N, Okabe N, Murono S, Tachibana K, Soeda S, Shimabukuro M, Saji S

Immunotherapy   1 - 10   2024.6（ ISSN:1750-743X ）

Real-world data on patients with early breast cancer who were prescribed abemaciclib adjuvant therapy in Japan.

Shimoi T, Pathadka S, Sekine N, Cai Z, Tanizawa Y, Kawaguchi T, Saji S, Yamashita T.

Future Oncol.   2024.5

Real-world data on patients with early breast cancer who were prescribed abemaciclib adjuvant therapy in Japan.

Shimoi T, Pathadka S, Sekine N, Cai Z, Tanizawa Y, Kawaguchi T, Saji S, Yamashita T

Future oncology (London, England)   1 - 10   2024.5（ ISSN:1479-6694 ）

Trastuzumab deruxtecan for human epidermal growth factor receptor 2-low advanced or metastatic breast cancer: recommendations from the Japanese Breast Cancer Society Clinical Practice Guidelines.

Hattori M, Honma N, Nagai S, Narui K, Shigechi T, Ozaki Y, Yoshida M, Sakatani T, Sasaki E, Tanabe Y, Tsurutani J, Takano T, Saji S, Masuda S, Horii R, Tsuda H, Yamaguchi R, Toyama T, Yamauchi C, Toi M, Yamamoto Y.

Breast Cancer.   31 ( 3 )   335 - 339   2024.5

The Japanese Breast Cancer Society Clinical Practice Guidelines for Breast Cancer, 2022 Edition: changes from the 2018 edition and general statements on breast cancer treatment.

Yamamoto Y, Yamauchi C, Toyama T, Nagai S, Sakai T, Kutomi G, Yoshimura M, Kawai M, Ohtani S, Kubota K, Nakashima K, Honma N, Yoshida M, Tokunaga E, Taira N, Iwata H, Saji S.

Breast Cancer.   31 ( 3 )   340 - 346   2024.5

The Japanese breast cancer society clinical practice guidelines for radiation treatment of breast cancer, 2022 edition.

Yoshimura M, Yamauchi C, Sanuki N, Hamamoto Y, Hirata K, Kawamori J, Kawamura M, Ogita M, Yamamoto Y, Iwata H, Saji S.

Breast Cancer.   31 ( 3 )   347 - 357   2024.5

Trastuzumab deruxtecan for human epidermal growth factor receptor 2-low advanced or metastatic breast cancer: recommendations from the Japanese Breast Cancer Society Clinical Practice Guidelines.

Hattori M, Honma N, Nagai S, Narui K, Shigechi T, Ozaki Y, Yoshida M, Sakatani T, Sasaki E, Tanabe Y, Tsurutani J, Takano T, Saji S, Masuda S, Horii R, Tsuda H, Yamaguchi R, Toyama T, Yamauchi C, Toi M, Yamamoto Y

Breast cancer (Tokyo, Japan)   31 ( 3 )   335 - 339   2024.5（ ISSN:1340-6868 ）

The Japanese breast cancer society clinical practice guidelines for radiation treatment of breast cancer, 2022 edition.

Yoshimura M, Yamauchi C, Sanuki N, Hamamoto Y, Hirata K, Kawamori J, Kawamura M, Ogita M, Yamamoto Y, Iwata H, Saji S

Breast cancer (Tokyo, Japan)   31 ( 3 )   347 - 357   2024.5（ ISSN:1340-6868 ）

The Japanese Breast Cancer Society Clinical Practice Guidelines for Breast Cancer, 2022 Edition: changes from the 2018 edition and general statements on breast cancer treatment.

Yamamoto Y, Yamauchi C, Toyama T, Nagai S, Sakai T, Kutomi G, Yoshimura M, Kawai M, Ohtani S, Kubota K, Nakashima K, Honma N, Yoshida M, Tokunaga E, Taira N, Iwata H, Saji S

Breast cancer (Tokyo, Japan)   31 ( 3 )   340 - 346   2024.5（ ISSN:1340-6868 ）

Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with early breast cancer.

Park KH, Loibl S, Sohn J, Park YH, Jiang Z, Tadjoedin H, Nag S, Saji S, Md Yusof M, Villegas EMB, Lim EH, Lu YS, Ithimakin S, Tseng LM, Dejthevaporn T, Chen TW, Lee SC, Galvez C, Malwinder S, Kogawa T, Bajpai J, Brahma B, Wang S, Curigliano G, Yoshino T, Kim SB, Pentheroudakis G, Im SA, Andre F, Ahn JB, Harbeck N

ESMO open   9 ( 5 )   102974   2024.5

Real-world data of HER2-negative early breast cancer patients treated with anthracycline and/or taxane regimens in Japan.

Shimomura A, Sagara Y, Koto R, Fujiwara M, Kanemura Y, Kitagawa H, Saji S.

Breast Cancer.   2024.4

Treatment patterns, healthcare resource utilization and outcomes for early stage triple-negative breast cancer in Japan.

Sanno H, Taniguchi K, Yoshimoto Y, Saji S

Future Oncol.   20 ( 13 )   833 - 849   2024.4

Identifying prognostic biomarkers for palbociclib add-on therapy in fulvestrant-resistant breast cancer using cell-free DNA sequencing.

Takeshita T, Iwamoto T, Niikura N, Watanabe K, Kikawa Y, Kobayashi K, Iwakuma N, Okamura T, Tada H, Ozaki S, Okuno T, Toh U, Yamamoto Y, Tsuneizumi M, Ishiguro H, Masuda N, Saji S

ESMO open   9 ( 4 )   102385   2024.4

Treatment patterns, healthcare resource utilization and outcomes for early stage triple-negative breast cancer in Japan.

Sanno H, Taniguchi K, Yoshimoto Y, Saji S

Future oncology (London, England)   20 ( 13 )   833 - 849   2024.4（ ISSN:1479-6694 ）

Protecting the Brain: Novel Strategies for Preventing Breast Cancer Brain Metastases through Selective Estrogen Receptor β Agonists and In Vitro Blood-Brain Barrier Models.

Kirchner J, Völker E, Shityakov S, Saji S, Förster CY.

Int J Mol Sci   25 ( 6 )   3379   2024.3

Protecting the Brain: Novel Strategies for Preventing Breast Cancer Brain Metastases through Selective Estrogen Receptor β Agonists and In Vitro Blood-Brain Barrier Models.

Kirchner J, Völker E, Shityakov S, Saji S, Förster CY

International journal of molecular sciences   25 ( 6 )   2024.3（ ISSN:16616596 ）

進行・再発乳癌に対する治療成績の向上について

佐治重衡

癌と化学療法.   51 ( 3 )   250 - 253   2024.3

Improved Outcomes in Advanced Metastatic Breast Cancer

Saji S.

Gan to kagaku ryoho. Cancer & chemotherapy   51 ( 3 )   250 - 253   2024.3（ ISSN:03850684 ）

The Japanese Breast Cancer Society clinical practice guidelines for epidemiology and prevention of breast cancer, 2022 edition.

Kawai M, Ohtani S, Iwasaki M, Yamamoto S, Takamatsu K, Okamura H, Arai M, Nomura T, Ozaki S, Shibata KI, Akabane A, Motoi F, Yamauchi C, Yamamoto Y, Iwata H, Saji S.

Breast Cancer.   31 ( 2 )   166 - 178   2024.3

2020 Annual Report of National Clinical Database-Breast Cancer Registry: 10-year mortality of elderly breast cancer patients in Japan.

Sagara Y, Kumamaru H, Niikura N, Miyashita M, Konishi T, Iwamoto T, Sanuki N, Tanakura K, Nagahashi M, Hayashi N, Yoshida M, Kinukawa N, Watanabe C, Toi M, Saji S.

Breast Cancer.   31 ( 2 )   179 - 184   2024.3

Survival trends and patient characteristics between 2004 and 2016 for breast cancer in Japan based on the National Clinical Database-Breast Cancer Registry.

Iwamoto T, Kumamaru H, Niikura N, Sagara Y, Miyashita M, Konishi T, Sanuki N, Tanakura K, Nagahashi M, Hayashi N, Yoshida M, Watanabe C, Kinukawa N, Toi M, Saji S.

Breast Cancer.   31 ( 2 )   185 - 194   2024.3

【切除不能進行・再発がんの治療成績の向上】進行・再発乳癌に対する治療成績の向上について

佐治 重衡

癌と化学療法   51 ( 3 )   250 - 253   2024.3（ ISSN:0385-0684 ）

The Japanese Breast Cancer Society clinical practice guidelines for epidemiology and prevention of breast cancer, 2022 edition.

Kawai M, Ohtani S, Iwasaki M, Yamamoto S, Takamatsu K, Okamura H, Arai M, Nomura T, Ozaki S, Shibata KI, Akabane A, Motoi F, Yamauchi C, Yamamoto Y, Iwata H, Saji S

Breast cancer (Tokyo, Japan)   31 ( 2 )   166 - 178   2024.3（ ISSN:1340-6868 ）

The Japanese Breast Cancer Society clinical practice guidelines for epidemiology and prevention of breast cancer, 2022 edition(タイトル和訳中)

Kawai Masaaki, Ohtani Shoichiro, Iwasaki Motoki, Yamamoto Seiichiro, Takamatsu Kiyoshi, Okamura Hitoshi, Arai Masami, Nomura Tsunehisa, Ozaki Shinji, Shibata Ken-ichi, Akabane Ayaka, Motoi Fuyuhiko, Yamauchi Chikako, Yamamoto Yutaka, Iwata Hiroji, Saji Shigehira, The Japanese breast cancer society

Breast Cancer   31 ( 2 )   166 - 178   2024.3（ ISSN:1340-6868 ）

Survival trends and patient characteristics between 2004 and 2016 for breast cancer in Japan based on the National Clinical Database-Breast Cancer Registry.

Iwamoto T, Kumamaru H, Niikura N, Sagara Y, Miyashita M, Konishi T, Sanuki N, Tanakura K, Nagahashi M, Hayashi N, Yoshida M, Watanabe C, Kinukawa N, Toi M, Saji S

Breast cancer (Tokyo, Japan)   31 ( 2 )   185 - 194   2024.3（ ISSN:1340-6868 ）

Survival trends and patient characteristics between 2004 and 2016 for breast cancer in Japan based on the National Clinical Database-Breast Cancer Registry(タイトル和訳中)

Iwamoto Takayuki, Kumamaru Hiraku, Niikura Naoki, Sagara Yasuaki, Miyashita Minoru, Konishi Takaaki, Sanuki Naoko, Tanakura Kenta, Nagahashi Masayuki, Hayashi Naoki, Yoshida Masayuki, Watanabe Chie, Kinukawa Naoko, Toi Masakazu, Saji Shigehira

Breast Cancer   31 ( 2 )   185 - 194   2024.3（ ISSN:1340-6868 ）

[Improved Outcomes in Advanced Metastatic Breast Cancer].

Saji S

Gan to kagaku ryoho. Cancer & chemotherapy   51 ( 3 )   250 - 253   2024.3（ ISSN:0385-0684 ）

2020 Annual Report of National Clinical Database-Breast Cancer Registry: 10-year mortality of elderly breast cancer patients in Japan.

Sagara Y, Kumamaru H, Niikura N, Miyashita M, Konishi T, Iwamoto T, Sanuki N, Tanakura K, Nagahashi M, Hayashi N, Yoshida M, Kinukawa N, Watanabe C, Toi M, Saji S

Breast cancer (Tokyo, Japan)   31 ( 2 )   179 - 184   2024.3（ ISSN:1340-6868 ）

2020 Annual Report of National Clinical Database-Breast Cancer Registry: 10-year mortality of elderly breast cancer patients in Japan(タイトル和訳中)

Sagara Yasuaki, Kumamaru Hiraku, Niikura Naoki, Miyashita Minoru, Konishi Takaaki, Iwamoto Takayuki, Sanuki Naoko, Tanakura Kenta, Nagahashi Masayuki, Hayashi Naoki, Yoshida Masayuki, Kinukawa Naoko, Watanabe Chie, Toi Masakazu, Saji Shigehira

Breast Cancer   31 ( 2 )   179 - 184   2024.3（ ISSN:1340-6868 ）

First-Line Ipatasertib, Atezolizumab, and Taxane Triplet for Metastatic Triple-Negative Breast Cancer: Clinical and Biomarker Results.

Schmid P, Turner NC, Barrios CH, Isakoff SJ, Kim SB, Sablin MP, Saji S, Savas P, Vidal GA, Oliveira M, O'Shaughnessy J, Italiano A, Espinosa E, Boni V, White S, Rojas B, Freitas-Junior R, Chae Y, Bondarenko I, Lee J, Torres Mattos C, Martinez Rodriguez JL, Lam L, Jones S, Reilly SJ, Huang X, Shah K, Dent R.

Clin Cancer Res.   30 ( 4 )   767 - 778   2024.2

First-Line Ipatasertib, Atezolizumab, and Taxane Triplet for Metastatic Triple-Negative Breast Cancer: Clinical and Biomarker Results.

Schmid P, Turner NC, Barrios CH, Isakoff SJ, Kim SB, Sablin MP, Saji S, Savas P, Vidal GA, Oliveira M, O'Shaughnessy J, Italiano A, Espinosa E, Boni V, White S, Rojas B, Freitas-Junior R, Chae Y, Bondarenko I, Lee J, Torres Mattos C, Martinez Rodriguez JL, Lam LH, Jones S, Reilly SJ, Huang X, Shah K, Dent R

Clinical cancer research : an official journal of the American Association for Cancer Research   30 ( 4 )   767 - 778   2024.2（ ISSN:1078-0432 ）

Risk factors for late recurrence and postrelapse survival in estrogen receptor (ER)-positive, human epidermal growth factor receptor (HER) 2-negative breast cancer after 5 years of endocrine therapy.

Ito M, Amari M, Sato A, Hikichi M, Sakamoto A, Yamazaki A, Saji S.

Breast   73   103604   2024.2

Risk factors for late recurrence and postrelapse survival in estrogen receptor (ER)-positive, human epidermal growth factor receptor (HER) 2-negative breast cancer after 5 years of endocrine therapy.

Ito M, Amari M, Sato A, Hikichi M, Sakamoto A, Yamazaki A, Saji S

Breast (Edinburgh, Scotland)   73   103604   2024.2（ ISSN:0960-9776 ）

The Japanese Breast Cancer Society Clinical Practice Guidelines for surgical treatment of breast cancer, 2022 edition.

Sakai T, Kutomi G, Shien T, Asaga S, Aruga T, Ishitobi M, Kuba S, Sawaki M, Terata K, Tomita K, Yamauchi C, Yamamoto Y, Iwata H, Saji S.

Breast Cancer.   31 ( 1 )   1 - 7   2024.1

Changes in cell-free DNA after short-term palbociclib and fulvestrant treatment for advanced or metastatic hormone receptor-positive and human epidermal growth factor 2-negative breast cancer.

Iwamoto T, Niikura N, Watanabe K, Takeshita T, Kikawa Y, Kobayashi K, Iwakuma N, Okamura T, Tada H, Ozaki S, Okuno T, Toh U, Yamamoto Y, Tsuneizumi M, Ishiguro H, Masuda N, Saji S.

Breast Cancer Res Treat.   203 ( 2 )   225 - 234   2024.1

Annual report of the Japanese Breast Cancer Registry for 2019.

Miyashita M, Kumamaru H, Niikura N, Sagara Y, Konishi T, Iwamoto T, Sanuki N, Tanakura K, Nagahashi M, Hayashi N, Yoshida M, Watanabe C, Kinukawa N, Toi M, Saji S.

Breast Cancer.   31 ( 1 )   16 - 23   2024.1

The Japanese breast cancer society clinical practice guidelines for pathological diagnosis of breast cancer, 2022 edition.

Honma N, Yoshida M, Kinowaki K, Horii R, Katsurada Y, Murata Y, Shimizu A, Tanabe Y, Yamauchi C, Yamamoto Y, Iwata H, Saji S.

Breast Cancer.   31 ( 1 )   8 - 15   2024.1

The Japanese Breast Cancer Society Clinical Practice Guidelines for surgical treatment of breast cancer, 2022 edition.

Sakai T, Kutomi G, Shien T, Asaga S, Aruga T, Ishitobi M, Kuba S, Sawaki M, Terata K, Tomita K, Yamauchi C, Yamamoto Y, Iwata H, Saji S

Breast cancer (Tokyo, Japan)   31 ( 1 )   1 - 7   2024.1（ ISSN:1340-6868 ）

The Japanese Breast Cancer Society Clinical Practice Guidelines for surgical treatment of breast cancer, 2022 edition(タイトル和訳中)

Sakai Takehiko, Kutomi Goro, Shien Tadahiko, Asaga Sota, Aruga Tomoyuki, Ishitobi Makoto, Kuba Sayaka, Sawaki Masataka, Terata Kaori, Tomita Koichi, Yamauchi Chikako, Yamamoto Yutaka, Iwata Hiroji, Saji Shigehira, The Japanese Breast Cancer Society

Breast Cancer   31 ( 1 )   1 - 7   2024.1（ ISSN:1340-6868 ）

The Japanese breast cancer society clinical practice guidelines for pathological diagnosis of breast cancer, 2022 edition.

Honma N, Yoshida M, Kinowaki K, Horii R, Katsurada Y, Murata Y, Shimizu A, Tanabe Y, Yamauchi C, Yamamoto Y, Iwata H, Saji S

Breast cancer (Tokyo, Japan)   31 ( 1 )   8 - 15   2024.1（ ISSN:1340-6868 ）

The Japanese breast cancer society clinical practice guidelines for pathological diagnosis of breast cancer, 2022 edition(タイトル和訳中)

Honma Naoko, Yoshida Masayuki, Kinowaki Keiichi, Horii Rie, Katsurada Yuka, Murata Yuya, Shimizu Ai, Tanabe Yuko, Yamauchi Chikako, Yamamoto Yutaka, Iwata Hiroji, Saji Shigehira, The Japanese breast cancer society

Breast Cancer   31 ( 1 )   8 - 15   2024.1（ ISSN:1340-6868 ）

Changes in cell-free DNA after short-term palbociclib and fulvestrant treatment for advanced or metastatic hormone receptor-positive and human epidermal growth factor 2-negative breast cancer.

Iwamoto T, Niikura N, Watanabe K, Takeshita T, Kikawa Y, Kobayashi K, Iwakuma N, Okamura T, Tada H, Ozaki S, Okuno T, Toh U, Yamamoto Y, Tsuneizumi M, Ishiguro H, Masuda N, Saji S

Breast cancer research and treatment   203 ( 2 )   225 - 234   2024.1（ ISSN:0167-6806 ）

Annual report of the Japanese Breast Cancer Registry for 2019.

Miyashita M, Kumamaru H, Niikura N, Sagara Y, Konishi T, Iwamoto T, Sanuki N, Tanakura K, Nagahashi M, Hayashi N, Yoshida M, Watanabe C, Kinukawa N, Toi M, Saji S

Breast cancer (Tokyo, Japan)   31 ( 1 )   16 - 23   2024.1（ ISSN:1340-6868 ）

Annual report of the Japanese Breast Cancer Registry for 2019(タイトル和訳中)

Miyashita Minoru, Kumamaru Hiraku, Niikura Naoki, Sagara Yasuaki, Konishi Takaaki, Iwamoto Takayuki, Sanuki Naoko, Tanakura Kenta, Nagahashi Masayuki, Hayashi Naoki, Yoshida Masayuki, Watanabe Chie, Kinukawa Naoko, Toi Masakazu, Saji Shigehira

Breast Cancer   31 ( 1 )   16 - 23   2024.1（ ISSN:1340-6868 ）

Patritumab Deruxtecan (HER3-DXd), a Human Epidermal Growth Factor Receptor 3-Directed Antibody-Drug Conjugate, in Patients With Previously Treated Human Epidermal Growth Factor Receptor 3-Expressing Metastatic Breast Cancer: A Multicenter, Phase I/II Trial.

Krop IE, Masuda N, Mukohara T, Takahashi S, Nakayama T, Inoue K, Iwata H, Yamamoto Y, Alvarez RH, Toyama T, Takahashi M, Osaki A, Saji S, Sagara Y, O'Shaughnessy J, Ohwada S, Koyama K, Inoue T, Li L, Patel P, Mostillo J, Tanaka Y, Sternberg DW, Sellami D, Yonemori K.

J Clin Oncol.   41 ( 36 )   5550 - 5560   2023.12

Patritumab Deruxtecan (HER3-DXd), a Human Epidermal Growth Factor Receptor 3-Directed Antibody-Drug Conjugate, in Patients With Previously Treated Human Epidermal Growth Factor Receptor 3-Expressing Metastatic Breast Cancer: A Multicenter, Phase I/II Trial.

Krop IE, Masuda N, Mukohara T, Takahashi S, Nakayama T, Inoue K, Iwata H, Yamamoto Y, Alvarez RH, Toyama T, Takahashi M, Osaki A, Saji S, Sagara Y, O'Shaughnessy J, Ohwada S, Koyama K, Inoue T, Li L, Patel P, Mostillo J, Tanaka Y, Sternberg DW, Sellami D, Yonemori K

Journal of clinical oncology : official journal of the American Society of Clinical Oncology   41 ( 36 )   5550 - 5560   2023.12（ ISSN:0732-183X ）

A risk-based subgroup analysis of the effect of adjuvant S-1 in estrogen receptor-positive, HER2-negative early breast cancer.

Takada M, Imoto S, Ishida T, Ito Y, Iwata H, Masuda N, Mukai H, Saji S, Ikeda T, Haga H, Saeki T, Aogi K, Sugie T, Ueno T, Ohno S, Ishiguro H, Kanbayashi C, Miyamoto T, Hagiwara Y, Toi M.

Breast Cancer Res Treat.   202 ( 3 )   485 - 496   2023.12

A risk-based subgroup analysis of the effect of adjuvant S-1 in estrogen receptor-positive, HER2-negative early breast cancer.

Takada M, Imoto S, Ishida T, Ito Y, Iwata H, Masuda N, Mukai H, Saji S, Ikeda T, Haga H, Saeki T, Aogi K, Sugie T, Ueno T, Ohno S, Ishiguro H, Kanbayashi C, Miyamoto T, Hagiwara Y, Toi M

Breast cancer research and treatment   202 ( 3 )   485 - 496   2023.12（ ISSN:0167-6806 ）

TROPION-Breast02: Datopotamab deruxtecan for locally recurrent inoperable or metastatic triple-negative breast cancer.

Dent RA, Cescon DW, Bachelot T, Jung KH, Shao ZM, Saji S, Traina TA, Vukovic P, Mapiye D, Maxwell MJ, Schmid P, Cortés J.

Future Oncol.   19 ( 35 )   2349 - 2359   2023.11

The Japanese Breast Cancer Society Clinical Practice Guidelines for systemic treatment of breast cancer, 2022 edition.

Terada M, Ito A, Kikawa Y, Koizumi K, Naito Y, Shimoi T, Ishihara M, Yamanaka T, Ozaki Y, Hara F, Nakamura R, Hattori M, Miyashita M, Kondo N, Yoshinami T, Takada M, Matsumoto K, Narui K, Sasada S, Iwamoto T, Hosoda M, Takano Y, Oba T, Sakai H, Murakami A, Higuchi T, Tsuchida J, Tanabe Y, Shigechi T, Tokuda E, Harao M, Kashiwagi S, Mase J, Watanabe J, Nagai SE, Yamauchi C, Yamamoto Y, Iwata H, Saji S, Toyama T.

Breast Cancer.   30 ( 6 )   872 - 884   2023.11

日本乳癌学会の乳癌診療ガイドライン2022年版(The Japanese Breast Cancer Society Clinical Practice Guidelines for systemic treatment of breast cancer, 2022 edition)

Terada Mitsuo, Ito Aki, Kikawa Yuichiro, Koizumi Kei, Naito Yoichi, Shimoi Tatsunori, Ishihara Mikiya, Yamanaka Takashi, Ozaki Yukinori, Hara Fumikata, Nakamura Rikiya, Hattori Masaya, Miyashita Minoru, Kondo Naoto, Yoshinami Tetsuhiro, Takada Masahiro, Matsumoto Koji, Narui Kazutaka, Sasada Shinsuke, Iwamoto Takayuki, Hosoda Mitsuchika, Takano Yuko, Oba Takaaki, Sakai Hitomi, Murakami Akari, Higuchi Toru, Tsuchida Junko, Tanabe Yuko, Shigechi Tomoko, Tokuda Emi, Harao Michiko, Kashiwagi Shinichiro, Mase Junichi, Watanabe Junichiro, Nagai Shigenori E., Yamauchi Chikako, Yamamoto Yutaka, Iwata Hiroji, Saji Shigehira, Toyama Tatsuya, The Japanese Breast Cancer Society(JBCS)

Breast Cancer   30 ( 6 )   872 - 884   2023.11（ ISSN:1340-6868 ）

TROPION-Breast02: Datopotamab deruxtecan for locally recurrent inoperable or metastatic triple-negative breast cancer.

Dent RA, Cescon DW, Bachelot T, Jung KH, Shao ZM, Saji S, Traina TA, Vukovic P, Mapiye D, Maxwell MJ, Schmid P, Cortés J

Future oncology (London, England)   19 ( 35 )   2349 - 2359   2023.11（ ISSN:1479-6694 ）

The Japanese Breast Cancer Society Clinical Practice Guidelines for systemic treatment of breast cancer, 2022 edition.

Terada M, Ito A, Kikawa Y, Koizumi K, Naito Y, Shimoi T, Ishihara M, Yamanaka T, Ozaki Y, Hara F, Nakamura R, Hattori M, Miyashita M, Kondo N, Yoshinami T, Takada M, Matsumoto K, Narui K, Sasada S, Iwamoto T, Hosoda M, Takano Y, Oba T, Sakai H, Murakami A, Higuchi T, Tsuchida J, Tanabe Y, Shigechi T, Tokuda E, Harao M, Kashiwagi S, Mase J, Watanabe J, Nagai SE, Yamauchi C, Yamamoto Y, Iwata H, Saji S, Toyama T

Breast cancer (Tokyo, Japan)   30 ( 6 )   872 - 884   2023.11（ ISSN:1340-6868 ）

Analysis of prognosis in different subtypes of invasive lobular carcinoma using the Japanese National Cancer Database-Breast Cancer Registry.

Adachi Y, Asaga S, Kumamaru H, Kinugawa N, Sagara Y, Niikura N, Jinno H, Saji S, Toi M.

Breast cancer research and treatment   201 ( 3 )   397 - 408   2023.10

Analysis of prognosis in different subtypes of invasive lobular carcinoma using the Japanese National Cancer Database-Breast Cancer Registry.

Adachi Y, Asaga S, Kumamaru H, Kinugawa N, Sagara Y, Niikura N, Jinno H, Saji S, Toi M

Breast cancer research and treatment   201 ( 3 )   397 - 408   2023.10（ ISSN:0167-6806 ）

Fulvestrant with or without anti-HER2 therapy in patients in a postmenopausal hormonal state and with ER-positive HER2-positive advanced or metastatic breast cancer: A subgroup analysis of data from the Safari study (JBCRG-C06).

Masuyama M, Masuda N, Kawaguchi H, Yamamoto Y, Saji S, Nakayama T, Aogi K, Anan K, Ohtani S, Sato N, Takano T, Tokunaga E, Nakamura S, Hasegawa Y, Hattori M, Fujisawa T, Morita S, Yamaguchi M, Yamashita T, Yotsumoto D, Toi M, Ohno S.

Cancer Med.   12 ( 17 )   17718 - 17730   2023.9

Fulvestrant with or without anti-HER2 therapy in patients in a postmenopausal hormonal state and with ER-positive HER2-positive advanced or metastatic breast cancer: A subgroup analysis of data from the Safari study (JBCRG-C06).

Masuyama M, Masuda N, Kawaguchi H, Yamamoto Y, Saji S, Nakayama T, Aogi K, Anan K, Ohtani S, Sato N, Takano T, Tokunaga E, Nakamura S, Hasegawa Y, Hattori M, Fujisawa T, Morita S, Yamaguchi M, Yamashita T, Yotsumoto D, Toi M, Ohno S

Cancer medicine   12 ( 17 )   17718 - 17730   2023.9

Alcohol consumption and breast cancer prognosis after breast cancer diagnosis: a systematic review and meta‑analysis of the Japanese Breast Cancer Society Clinical Practice Guideline, 2022 edition.

Nomura T, Kawai M, Fukuma Y, Koike Y, Ozaki S, Iwasaki M, Yamamoto S, Takamatsu K, Okamura H, Arai M, Ootani S, Iwata H, Saji S.

Breast Cancer.   30 ( 4 )   519 - 530   2023.7

乳癌診断後の飲酒と乳癌予後　乳癌診療ガイドライン2022年版の系統的レビューとメタ解析(Alcohol consumption and breast cancer prognosis after breast cancer diagnosis: a systematic review and meta-analysis of the Japanese Breast Cancer Society Clinical Practice Guideline, 2022 edition)

Nomura Tsunehisa, Kawai Masaaki, Fukuma Yuna, Koike Yoshikazu, Ozaki Shinji, Iwasaki Motoki, Yamamoto Seiichiro, Takamatsu Kiyoshi, Okamura Hitoshi, Arai Masami, Ootani Shoichiro, Iwata Hiroji, Saji Shigehira

Breast Cancer   30 ( 4 )   519 - 530   2023.7（ ISSN:1340-6868 ）

Postoperative Adjuvant Anastrozole for 10 or 5 Years in Patients With Hormone Receptor-Positive Breast Cancer: AERAS, a Randomized Multicenter Open-Label Phase III Trial.

Iwase T, Saji S, Iijima K, Higaki K, Ohtani S, Sato Y, Hozumi Y, Hasegawa Y, Yanagita Y, Takei H, Tanaka M, Masuoka H, Tanabe M, Egawa C, Komoike Y, Nakamura T, Ohtsu H, Mukai H.

J Clin Oncol.   41 ( 18 )   3329 - 3338   2023.6（ ISSN:0732-183X ）

Capivasertib in Hormone Receptor-Positive Advanced Breast Cancer.

Turner NC, Oliveira M, Howell SJ, Dalenc F, Cortes J, Gomez Moreno HL, Hu X, Jhaveri K, Krivorotko P, Loibl S, Morales Murillo S, Okera M, Park YH, Sohn J, Toi M, Tokunaga E, Yousef S, Zhukova L, de Bruin EC, Grinsted L, Schiavon G, Foxley A, Rugo HS; CAPItello-291 Study Group.

N Engl J Med.   388 ( 22 )   2058 - 2070   2023.6

Fulvestrant plus palbociclib in advanced or metastatic hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancer after fulvestrant monotherapy: Japan Breast Cancer Research Group-M07 (FUTURE trial).

Watanabe K, Niikura N, Kikawa Y, Oba M, Kobayashi K, Tada H, Ozaki S, Toh U, Yamamoto Y, Tsuneizumi M, Okuno T, Iwakuma N, Takeshita T, Iwamoto T, Ishiguro H, Masuda N, Saji S

Breast cancer research and treatment   199 ( 2 )   253 - 263   2023.6（ ISSN:0167-6806 ）

The review of clinical study JBCRG-ABCD project

Cancer Board of the Breast   7 ( 2 )   67 - 67   2023.5

The review of clinical study　JBCRG-ABCD project: Advanced Breast Cancer Database(ABCD) project

新倉 直樹, 相良 安昭, 佐治 重衡

Cancer Board of the Breast   7 ( 2 )   133 - 133   2023.5（ ISSN:2189-356X ）

Claudin-4-adhesion signaling drives breast cancer metabolism and progression via liver X receptor β.

Murakami-Nishimagi Y, Sugimoto K, Kobayashi M, Tachibana K, Kojima M, Okano M, Hashimoto Y, Saji S, Ohtake T, Chiba H

25 ( 1 )   41   2023.4（ ISSN:1465-5411 ）

血管肉腫の同胞発症がみられた1家系

勝部暢介, 佐治重衡, 岡野舞子, 石野淳, 高橋昌一, 後藤政広, 牛尼美年子, 菅 野康吉, 吉田輝彦, 野水整

遺伝性腫瘍   22 ( 4 )   106 - 111   2023.3

Retrospective study on the effectiveness of medroxyprogesterone acetate in the treatment of ER-positive/HER2-negative post-menopausal advanced breast cancer: an additional analysis of the JBCRG-C06 Safari study.

Kawaguchi H, Yamamoto Y, Saji S, Masuda N, Nakayama T, Aogi K, Anan K, Ohtani S, Sato N, Takano T, Tokunaga E, Nakamura S, Hasegawa Y, Hattori M, Fujisawa T, Morita S, Yamaguchi M, Yamashita T, Yotsumoto D, Toi M, Ohno S.

Jpn J Clin Oncol   53 ( 3 )   203 - 211   2023.3（ ISSN:0368-2811 ）

血管肉腫の同胞発症がみられた1家系

勝部 暢介, 佐治 重衡, 岡野 舞子, 石野 淳, 高橋 昌一, 後藤 政広, 牛尼 美年子, 菅野 康吉, 吉田 輝彦, 野水 整

遺伝性腫瘍   22 ( 4 )   106 - 111   2023.3

ER陽性/HER2陰性閉経後進行乳癌の治療におけるに対するメドロキシプロゲステロン酢酸エステルの有効性に関する後ろ向き研究　JBCRG-C06 Safari試験の追加解析(Retrospective study on the effectiveness of medroxyprogesterone acetate in the treatment of ER-positive/HER2-negative post-menopausal advanced breast cancer: an additional analysis of the JBCRG-C06 Safari study)

Kawaguchi Hidetoshi, Yamamoto Yutaka, Saji Shigehira, Masuda Norikazu, Nakayama Takahiro, Aogi Kenjiro, Anan Keisei, Ohtani Shoichiro, Sato Nobuaki, Takano Toshimi, Tokunaga Eriko, Nakamura Seigo, Hasegawa Yoshie, Hattori Masaya, Fujisawa Tomomi, Morita Satoshi, Yamaguchi Miki, Yamashita Toshinari, Yotsumoto Daisuke, Toi Masakazu, Ohno Shinji

Japanese Journal of Clinical Oncology   53 ( 3 )   203 - 211   2023.3（ ISSN:0368-2811 ）

E3 Ubiquitin Ligase NEDD4 Affects Estrogen Receptor α Expression and the Prognosis of Patients with Hormone Receptor-Positive Breast Cancer

Natori Y, Suga J, Tokuda E, Tachibana K, Imai J, Honma R, Azami Y, Noda M, Sasaki E, Watanabe S, Ohtake T, Saji S.

Cancers   15 ( 2 )   539   2023.1（ ISSN:2072-6694 ）

Efficacy and exploratory biomarker analysis of entinostat plus exemestane in advanced or recurrent breast cancer: phase II randomized controlled trial.

Iwata H, Nakamura R, Masuda N, Yamashita T, Yamamoto Y, Kobayashi K, Tsurutani J, Iwasa T, Yonemori K, Tamura K, Aruga T, Tokunaga E, Kaneko K, Lee MJ, Yuno A, Kawabata A, Seike T, Kaneda A, Nishimura Y, Trepel JB, Saji S.

Jpn J Clin Oncol   53 ( 1 )   4 - 15   2023.1

【がん免疫療法の診断と治療の現状と展望】がん抗体療法の進歩　乳がんHER2抗体薬物複合体などの抗体療法の現状と進歩

名取 穣, 佐治 重衡

Vita   40 ( 1 )   37 - 41   2023.1（ ISSN:0915-1028 ）

進行性または再発性乳癌に対するエンチノスタット+エキセメスタンの有効性と探索的バイオマーカー解析　第II相無作為化比較試験(Efficacy and exploratory biomarker analysis of entinostat plus exemestane in advanced or recurrent breast cancer: phase II randomized controlled trial)

Iwata Hiroji, Nakamura Rikiya, Masuda Norikazu, Yamashita Toshinari, Yamamoto Yutaka, Kobayashi Kokoro, Tsurutani Junji, Iwasa Tsutomu, Yonemori Kan, Tamura Kenji, Aruga Tomoyuki, Tokunaga Eriko, Kaneko Koji, Lee Min-Jung, Yuno Akira, Kawabata Azusa, Seike Toshihiro, Kaneda Ayumi, Nishimura Yozo, Trepel Jane B., Saji Shigehira

Japanese Journal of Clinical Oncology   53 ( 1 )   4 - 15   2023.1（ ISSN:0368-2811 ）

Successful management of pelvic recurrence of MSI-High endometrial cancer by total pelvic exenteration followed by administration of pembrolizumab:A case report.

Kojima M, Soeda S, Okabe C, Sato T, Kamo N, Ueda M, Endo Y, Nomura S, Tokuda E, Furukawa S, Kataoka M, Fujita S, Saji S, Watanabe T, Fujimori K.

Fukushima J Med Sci.   68 ( 3 )   191 - 195   2022.12

Successful management of pelvic recurrence of MSI-High endometrial cancer by total pelvic exenteration followed by administration of pembrolizumab:A case report.

Kojima M, Soeda S, Okabe C, Sato T, Kamo N, Ueda M, Endo Y, Nomura S, Tokuda E, Furukawa S, Kataoka M, Fujita S, Saji S, Watanabe T, Fujimori K

Fukushima journal of medical science   68 ( 3 )   191 - 195   2022.12（ ISSN:0016-2590 ）

骨盤内臓器全摘出術後のペムブロリズマブ投与による高頻度MSI子宮内膜癌の骨盤再発の管理に成功した一症例(Successful management of pelvic recurrence of MSI-High endometrial cancer by total pelvic exenteration followed by administration of pembrolizumab: A case report)

Kojima Manabu, Soeda Shu, Okabe Chikako, Sato Tetsu, Kamo Norihito, Ueda Makiko, Endo Yuta, Nomura Shinji, Tokuda Emi, Furukawa Shigenori, Kataoka Masao, Fujita Shotaro, Saji Shigehira, Watanabe Takafumi, Fujimori Keiya

Fukushima Journal of Medical Science   68 ( 3 )   191 - 195   2022.12（ ISSN:0016-2590 ）

Subgroup analysis of Japanese patients in a phase III randomized, controlled study of neoadjuvant atezolizumab or placebo, combined with nab-paclitaxel and anthracycline-based chemotherapy in early triple-negative breast cancer (IMpassion031).

Saji S, Ohsumi S, Ito M, Hayashi N, Kobayashi K, Masuda N, Niikura N, Yamashita T, Kiyama K, Hasegawa A, Nakagawa S, Hattori M.

Jpn J Clin Oncol.   52 ( 10 )   1124 - 1133   2022.10

早期トリプルネガティブ乳癌に対する術前補助アテゾリズマブまたはプラセボおよびナブパクリタキセルとアントラサイクリンベース化学療法との併用療法の第III相無作為化比較試験における日本人患者のサブグループ解析(IMpassion031)(Subgroup analysis of Japanese patients in a phase III randomized, controlled study of neoadjuvant atezolizumab or placebo, combined with nab-paclitaxel and anthracycline-based chemotherapy in early triple-negative breast cancer(IMpassion031))

Saji Shigehira, Ohsumi Shozo, Ito Mitsuya, Hayashi Naoki, Kobayashi Kokoro, Masuda Norikazu, Niikura Naoki, Yamashita Toshinari, Kiyama Keiichiro, Hasegawa Ayumi, Nakagawa Shizuka, Hattori Masaya

Japanese Journal of Clinical Oncology   52 ( 10 )   1124 - 1133   2022.10（ ISSN:0368-2811 ）

Patient-reported outcomes from a randomized trial of neoadjuvant atezolizumab-chemotherapy in early triple-negative breast cancer.

Barrios CH, Saji S, Harbeck N, Zhang H, Jung KH, Patel S, Patel S, Duc AN, Liste-Hermoso M, Chui SY, Mittendorf EA

NPJ Breast Cancer.   8 ( 1 )   108   2022.9

Pertuzumab retreatment for HER2-positive advanced breast cancer: A randomized, open-label phase III study (PRECIOUS).

Yamamoto Y, Iwata H, Taira N, Masuda N, Takahashi M, Yoshinami T, Ueno T, Toyama T, Yamanaka T, Takano T, Kashiwaba M, Tsugawa K, Hasegawa Y, Tamura K, Tada H, Hara F, Fujisawa T, Niikura N, Saji S, Morita S, Toi M, Ohno S.

Cancer Sci.   113 ( 9 )   3169 - 3179   2022.9

Prognostic Role of Carcinoembryonic Antigen and Carbohydrate Antigen 19-9 in Stage IV Colorectal Cancer.

Kawamura H, Honda M, Takano Y, Kinuta S, Kamiga T, Saji S, Kono K.

Anticancer Res.   42 ( 8 )   3921 - 3928   2022.8

Validation of a nuclear grading system for resected stage I-IIIA, high-risk, node-negative invasive breast carcinoma in the N·SAS-BC 01 trial.

Tsuda H, Kurosumi M, Akiyama F, Ohno S, Saji S, Masuda N, Shimomura A, Sato N, Takao S, Ohsumi S, Tokuda Y, Inaji H, Watanabe T

Breast cancer (Tokyo, Japan)   29 ( 4 )   720 - 729   2022.7（ ISSN:1340-6868 ）

Factors associated with overall survival after recurrence in patients with ER-positive/HER2-negative postmenopausal breast cancer: an ad hoc analysis of the JBCRG-C06 Safari study.

Kawaguchi H, Yamamoto Y, Saji S, Masuda N, Nakayama T, Aogi K, Anan K, Ito Y, Ohtani S, Sato N, Takano T, Tokunaga E, Nakamura S, Hasegawa Y, Hattori M, Fujisawa T, Morita S, Yamaguchi M, Yamashita H, Yamashita T, Yotsumoto D, Toi M, Ohno S.

Jpn J Clin Oncol.   52 ( 6 )   545 - 553   2022.5

Switch maintenance endocrine therapy plus bevacizumab after bevacizumab plus paclitaxel in advanced or metastatic oestrogen receptor-positive, HER2-negative breast cancer (BOOSTER): a randomised, open-label, phase 2 trial.

Saji S, Taira N, Kitada M, Takano T, Takada M, Ohtake T, Toyama T, Kikawa Y, Hasegawa Y, Fujisawa T, Kashiwaba M, Ishida T, Nakamura R, Yamamoto Y, Toh U, Iwata H, Masuda N, Morita S, Ohno S, Toi M.

Lancet Oncol.   23 ( 5 )   636 - 649   2022.5

Evaluation of a novel medical device for pegfilgrastim administration.

Aruga T, Doihara H, Yanagita Y, Ishida T, Yamashita T, Uehara K, Taira T, Tsurutani J, Takeshita T, Tsuyuki S, Kaneko K, Ohtake T, Yamaguchi Y, Hara Y, Saji S.

Cancer Sci.   113 ( 5 )   1763 - 1770   2022.5

Immune microenvironment, homologous recombination deficiency, and therapeutic response to neoadjuvant chemotherapy in triple-negative breast cancer: Japan Breast Cancer Research Group (JBCRG)22 TR

Ueno T, Kitano S, Masuda N, Ikarashi D, Yamashita M, Chiba T, Kadoya T, Bando H, Yamanaka T, Ohtani S, Nagai S, Nakayama T, Takahashi M, Saji S, Aogi K, Velaga R, Kawaguchi K, Morita S, Haga H, Ohno S, Toi M.

BMC Med.   20 ( 1 )   136   2022.4

A rare case of recurrent ovarian cancer with TPM3-NTRK1 gene rearrangement: A case report.

Endo Y, Watanabe T, Saito M, Saito K, Suzuki R, Sano H, Natori Y, Sasaki E, Ueda M, Kamo N, Furukawa S, Soeda S, Kono K, Saji S, Fujimori K.

Mol Clin Oncol   16 ( 4 )   90   2022.4

Japan Society of Clinical Oncology Clinical Practice Guidelines 2017 for fertility preservation in childhood, adolescent, and young adult cancer patients: part 1.

Harada M, Kimura F, Takai Y, Nakajima T, Ushijima K, Kobayashi H, Satoh T, Tozawa A, Sugimoto K, Saji S, Shimizu C, Akiyama K, Bando H, Kuwahara A, Furui T, Okada H, Kawai K, Shinohara N, Nagao K, Kitajima M, Suenobu S, Soejima T, Miyachi M, Miyoshi Y, Yoneda A, Horie A, Ishida Y, Usui N, Kanda Y, Fujii N, Endo M, Nakayama R, Hoshi M, Yonemoto T, Kiyotani C, Okita N, Baba E, Muto M, Kikuchi I, Morishige KI, Tsugawa K, Nishiyama H, Hosoi H, Tanimoto M, Kawai A, Sugiyama K, Boku N, Yonemura M, Hayashi N, Aoki D, Osuga Y, Suzuki N.

Int J Clin Oncol.   27 ( 2 )   265 - 280   2022.2（ ISSN:1341-9625 ）

Japan Society of Clinical Oncology Clinical Practice Guidelines 2017 for fertility preservation in childhood, adolescent, and young adult cancer patients: part 2.

Tozawa A, Kimura F, Takai Y, Nakajima T, Ushijima K, Kobayashi H, Satoh T, Harada M, Sugimoto K, Saji S, Shimizu C, Akiyama K, Bando H, Kuwahara A, Furui T, Okada H, Kawai K, Shinohara N, Nagao K, Kitajima M, Suenobu S, Soejima T, Miyachi M, Miyoshi Y, Yoneda A, Horie A, Ishida Y, Usui N, Kanda Y, Fujii N, Endo M, Nakayama R, Hoshi M, Yonemoto T, Kiyotani C, Okita N, Baba E, Muto M, Kikuchi I, Morishige KI, Tsugawa K, Nishiyama H, Hosoi H, Tanimoto M, Kawai A, Sugiyama K, Boku N, Yonemura M, Hayashi N, Aoki D, Suzuki N, Osuga Y

Int J Clin Oncol.   27 ( 2 )   281 - 300   2022.2

Ipatasertib plus paclitaxel for PIK3CA/AKT1/PTEN-altered hormone receptor-positive HER2-negative advanced breast cancer: primary results from cohort B of the IPATunity130 randomized phase 3 trial.

Turner N, Dent RA, O'Shaughnessy J, Kim SB, Isakoff SJ, Barrios C, Saji S, Bondarenko I, Nowecki Z, Lian Q, Reilly SJ, Hinton H, Wongchenko MJ, Kovic B, Mani A, Oliveira M.

Breast cancer research and treatment   191 ( 3 )   565 - 576   2022.2（ ISSN:0167-6806 ）

ESMO 2021 meeting report 1)乳がん

佐治重衡

腫瘍内科   29 ( 2 )   226 - 231   2022.2

Trends in adjuvant therapy after breast-conserving surgery for ductal carcinoma in situ of breast: a retrospective cohort study using the National Breast Cancer Registry of Japan.

Yotsumoto D, Sagara Y, Kumamaru H, Niikura N, Miyata H, Kanbayashi C, Tsuda H, Yamamoto Y, Aogi K, Kubo M, Tamura K, Hayashi N, Miyashita M, Kadoya T, Saji S, Toi M, Imoto S, Jinno H

Breast Cancer.   29 ( 1 )   1 - 8   2022.1（ ISSN:1340-6868 ）

非浸潤性乳管癌に対する乳房温存手術後補助療法の傾向　全国乳癌登録を用いた後ろ向きコホート研究(Trends in adjuvant therapy after breast-conserving surgery for ductal carcinoma in situ of breast: a retrospective cohort study using the National Breast Cancer Registry of Japan)

Yotsumoto Daisuke, Sagara Yasuaki, Kumamaru Hiraku, Niikura Naoki, Miyata Hiroaki, Kanbayashi Chizuko, Tsuda Hitoshi, Yamamoto Yutaka, Aogi Kenjiro, Kubo Makoto, Tamura Kenji, Hayashi Naoki, Miyashita Minoru, Kadoya Takayuki, Saji Shigehira, Toi Masakazu, Imoto Shigeru, Jinno Hiromitsu

Breast Cancer   29 ( 1 )   1 - 8   2022.1（ ISSN:1340-6868 ）

Trend in Cancer incidence and mortality in Fukushima between 2008 and 2015.

Shibata A, Saji S, Kamiya K, Yasumura S.

J Epidemiol.   31 ( 12 )   653 - 659   2021.12

Trend in Cancer Incidence and Mortality in Fukushima From 2008 Through 2015.

Shibata A, Saji S, Kamiya K, Yasumura S

Journal of epidemiology   31 ( 12 )   653 - 659   2021.12（ ISSN:0917-5040 ）

The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group

El Bairi K., Haynes H.R., Blackley E., Fineberg S., Shear J., Turner S., de Freitas J.R., Sur D., Amendola L.C., Gharib M., Gharib M., Kallala A., Arun I., Azmoudeh-Ardalan F., Fujimoto L., Liu S.W., Lien H.C., Lien H.C., Kirtani P., Balancin M., El Attar H., Yang W., Yang W., Chen I.C., Chen I.C., Bautista V., Do Prado Moura J.F., Castaneda C., Spengler E., Acosta-Haab G., Frahm I., Sanchez J., Castillo M., Bouchmaa N., Md Zin R.R., Shui R., Onyuma T., Yang W., Husain Z., Willard-Gallo K., Coosemans A., Perez E.A., Provenzano E., Ericsson P.G., Richardet E., Mehrotra R., Sarancone S., Ehinger A., Rimm D.L., Bartlett J.M.S., Viale G., Denkert C., Hida A.I., Sotiriou C., Loibl S., Hewitt S.M., Badve S., Symmans W.F., Kim R.S., Pruneri G., Goel S., Francis P.A., Inurrigarro G., Yamaguchi R., Garcia-Rivello H., Horlings H., Afqir S., Salgado R., Adams S., Kok M., Dieci M.V., Michiels S., Demaria S., Loi S., El Bairi K., Turner S., Sua L.F., Liu S.W., Guleria P., Shash E.

NPJ Breast Cancer.   7 ( 1 )   150   2021.12

Development of CDK4 & 6 Inhibitor Abemaciclib in Breast Cancer

Masuda N, Saji S, Kawaguchi T, Chen Y, Ohno S.

48 ( 12 )   1475 - 1483   2021.12

福島県における2008年～2015年までの癌の罹患率と死亡率の傾向(Trend in Cancer Incidence and Mortality in Fukushima From 2008 Through 2015)

Shibata Akiko, Saji Shigehira, Kamiya Kenji, Yasumura Seiji

Journal of Epidemiology   31 ( 11-12 )   653 - 659   2021.12（ ISSN:0917-5040 ）

Phase 1 trial of entinostat as monotherapy and combined with exemestane in Japanese patients with hormone receptor-positive advanced breast cancer.

Masuda N, Tamura K, Yasojima H, Shimomura A, Sawaki M, Lee MJ, Yuno A, Trepel J, Kimura R, Nishimura Y, Saji S, Iwata H.

BMC Cancer.   21 ( 1 )   1269 - 1269   2021.11

Clinical Impact of Primary Tumor Site in Stage IV Colorectal Cancer: A Statewide Cohort Study.

Kawamura H, Honda M, Takiguchi K, Kamiga T, Saito K, Muto A, Shiraso S, Yamashita N, Iwao T, Saji S, Kono K, Konno S.

Anticancer Research   41 ( 11 )   5693 - 5702   2021.11（ ISSN:0250-7005 ）

Systemic therapy and prognosis of older patients with stage II/III breast cancer: A large-scale analysis of the Japanese Breast Cancer Registry.

Yamada A, Kumamaru H, Shimizu C, Taira N, Nakayama K, Miyashita M, Honma N, Miyata H, Endo I, Saji S, Sawaki M

European journal of cancer (Oxford, England : 1990)   154   157 - 166   2021.9（ ISSN:0959-8049 ）

早期乳がんに対する2つのCDK4／6阻害薬 第Ⅲ相臨床試験の結果から：PALLAS試験とmonarchE試験

名取 穣, 佐治 重衡

がん分子標的治療   19 ( 1 )   112 - 115   2021.9

早期乳がんに対する2つのCDK4/6阻害薬　第III相臨床試験の結果から:PALLAS試験とmonarchE試験

名取 穣, 佐治 重衡

がん分子標的治療   19 ( 1 )   112 - 115   2021.9（ ISSN:1347-6955 ）

早期乳がんに対する2つのCDK4／6阻害薬 第Ⅲ相臨床試験の結果から：PALLAS試験とmonarchE試験

名取 穣, 佐治 重衡

がん分子標的治療   19 ( 1 )   112 - 115   2021.9

Correction to: The Japanese Breast Cancer Society Clinical Practice Guidelines for Breast Cancer Screening and Diagnosis, 2018 Edition.

Uematsu T, Nakashima K, Kikuchi M, Kubota K, Suzuki A, Nakano S, Hirokaga K, Yamaguchi K, Saji S, Iwata H

Breast cancer (Tokyo, Japan)   28 ( 4 )   983 - 984   2021.7（ ISSN:1340-6868 ）

Correction to: The Japanese Breast Cancer Society Clinical Practice Guidelines for systemic treatment of breast cancer, 2018 edition.

Tatsunori Shimoi, Shigenori E Nagai, Tetsuhiro Yoshinami, Masato Takahashi, Hitoshi Arioka, Mikiya Ishihara, Yuichiro Kikawa, Kei Koizumi, Naoto Kondo, Yasuaki Sagara, Masahiro Takada, Toshimi Takano, Junji Tsurutani, Yoichi Naito, Rikiya Nakamura, Masaya Hattori, Fimikata Hara, Naoki Hayashi, Toshiro Mizuno, Minoru Miyashita, Nami Yamashita, Takashi Yamanaka, Shigehira Saji, Hiroji Iwata, Tatsuya Toyama

Breast cancer (Tokyo, Japan)   28 ( 4 )   985 - 986   2021.7（ ISSN:1340-6868 ）

Correction to: The Japanese Breast Cancer Society clinical practice guidelines for surgical treatment of breast cancer, 2018 edition.

Inokuchi M, Kutomi G, Kijima Y, Sakai T, Sawaki M, Shien T, Hanamura N, Yano K, Wada N, Saji S, Iwata H

Breast cancer (Tokyo, Japan)   28 ( 4 )   989   2021.7（ ISSN:1340-6868 ）

Chromosomal translocation t(11;14) and p53 deletion induced by the CRISPR/Cas9 system in normal B cell-derived iPS cells.

Azami Y, Tsuyama N, Abe Y, Sugai-Takahashi M, Kudo KI, Ota A, Sivasundaram K, Muramatsu M, Shigemura T, Sasatani M, Hashimoto Y, Saji S, Kamiya K, Hanamura I, Ikezoe T, Onodera M, Sakai A

Scientific reports   11 ( 1 )   5216   2021.3

Recommendations for the management of breast cancer patients during the COVID-19 pandemic from the Japan Breast Cancer Society.

Kawate T, Yoshida A, Sugae S, Asaga S, Kaise H, Saji S, Yamauchi C, Miyoshi Y, Yamauchi H, Ishikawa T

Breast cancer   28 ( 2 )   247 - 253   2021.3（ ISSN:1340-6868 ）

日本乳癌学会によるCOVID-19パンデミック時の乳癌患者の診療に関する推奨事項(Recommendations for the management of breast cancer patients during the COVID-19 pandemic from the Japan Breast Cancer Society)

Kawate Takahiko, Yoshida Atsushi, Sugae Sadatoshi, Asaga Souta, Kaise Hiroshi, Saji Shigehira, Yamauchi Chikako, Miyoshi Yasuo, Yamauchi Hideko, Ishikawa Takashi, the Japan Breast Cancer Society

Breast Cancer   28 ( 2 )   247 - 253   2021.3（ ISSN:1340-6868 ）

Relationships between pathological factors and long-term outcomes in patients enrolled in two prospective randomized controlled trials comparing the efficacy of oral tegafur-uracil with CMF (N·SAS-BC 01 trial and CUBC trial).

Ohno S, Saji S, Masuda N, Tsuda H, Akiyama F, Kurosumi M, Shimomura A, Sato N, Takao S, Ohsumi S, Tokuda Y, Inaji H, Watanabe T, Ohashi Y

Breast cancer research and treatment   186 ( 1 )   135 - 147   2021.2（ ISSN:0167-6806 ）

Clinicopathological characteristics, practical treatments, prognosis, and clinical issues of older breast cancer patients in Japan.

Sawaki M, Yamada A, Kumamaru H, Miyata H, Nakayama K, Shimizu C, Miyashita M, Honma N, Taira N, Saji S

Breast cancer   28 ( 1 )   1 - 8   2021.1（ ISSN:1340-6868 ）

Adjuvant S-1 plus endocrine therapy for oestrogen receptor-positive, HER2-negative, primary breast cancer: a multicentre, open-label, randomised, controlled, phase 3 trial.

Toi M, Imoto S, Ishida T, Ito Y, Iwata H, Masuda N, Mukai H, Saji S, Shimizu A, Ikeda T, Haga H, Saeki T, Aogi K, Sugie T, Ueno T, Kinoshita T, Kai Y, Kitada M, Sato Y, Jimbo K, Sato N, Ishiguro H, Takada M, Ohashi Y, Ohno S

The Lancet. Oncology   22 ( 1 )   74 - 84   2021.1（ ISSN:1470-2045 ）

日本の高齢乳癌患者の臨床病理学的特徴、practical treatment、予後、臨床上の問題点(Clinicopathological characteristics, practical treatments, prognosis, and clinical issues of older breast cancer patients in Japan)

Sawaki Masataka, Yamada Akimitsu, Kumamaru Hiraku, Miyata Hiroaki, Nakayama Kanako, Shimizu Chikako, Miyashita Mika, Honma Naoko, Taira Naruto, Saji Shigehira

Breast Cancer   28 ( 1 )   1 - 8   2021.1（ ISSN:1340-6868 ）

Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial.

Mittendorf EA, Zhang H, Barrios CH, Saji S, Jung KH, Hegg R, Koehler A, Sohn J, Iwata H, Telli ML, Ferrario C, Punie K, Penault-Llorca F, Patel S, Duc AN, Liste-Hermoso M, Maiya V, Molinero L, Chui SY, Harbeck N.

Lancet.   396 ( 10257 )   1090 - 1100   2020.10

Risk of immunotherapy-related narcolepsy in genetically predisposed patients: a case report of narcolepsy after administration of pembrolizumab.

Natori Y, Sasaki E, Soeda S, Furukawa S, Azami Y, Tokuda E, Kanbayashi T, Saji S.

Journal for immunotherapy of cancer   8 ( 2 )   e001164 - e001164   2020.10

談論　がんゲノム医療の現状について

佐治 重衡

福島県病院協会会報   111   3 - 5   2020.6

Trastuzumab, pertuzumab, and eribulin mesylate versus trastuzumab, pertuzumab, and a taxane as a first-line or second-line treatment for HER2-positive, locally advanced or metastatic breast cancer: study protocol for a randomized controlled, non-inferiority, phase III trial in Japan (JBCRG-M06/EMERALD).

Yamashita T, Masuda N, Saji S, Araki K, Ito Y, Takano T, Takahashi M, Tsurutani J, Koizumi K, Kitada M, Kojima Y, Sagara Y, Tada H, Iwasa T, Kadoya T, Iwatani T, Hasegawa H, Morita S, Ohno S

Trials   21 ( 1 )   391   2020.5

The Japanese Breast Cancer Society Clinical Practice Guidelines for systemic treatment of breast cancer, 2018 edition.

Shimoi T, Nagai SE, Yoshinami T, Takahashi M, Arioka H, Ishihara M, Kikawa Y, Koizumi K, Kondo N, Sagara Y, Takada M, Takano T, Tsurutani J, Naito Y, Nakamura R, Hattori M, Hara F, Hayashi N, Mizuno T, Miyashita M, Yamashita N, Yamanaka T, Saji S, Iwata H, Toyama T.

Breast Cancer.   27 ( 3 )   322 - 331   2020.5（ ISSN:1340-6868 ）

Factors associated with prolonged overall survival in patients with postmenopausal estrogen receptor-positive advanced breast cancer using real-world data: a follow-up analysis of the JBCRG-C06 Safari study.

Kawaguchi H, Masuda N, Nakayama T, Aogi K, Anan K, Ito Y, Ohtani S, Sato N, Saji S, Takano T, Tokunaga E, Nakamura S, Hasegawa Y, Hattori M, Fujisawa T, Morita S, Yamaguchi M, Yamashita H, Yamashita T, Yamamoto Y, Yotsumoto D, Toi M, Ohno S

Breast cancer (Tokyo, Japan)   27 ( 3 )   389 - 398   2020.5（ ISSN:1340-6868 ）

Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with early breast cancer: a KSMO-ESMO initiative endorsed by CSCO, ISMPO, JSMO, MOS, SSO and TOS

Park Y H, Senkus-Konefka E, Im S A, Pentheroudakis G, Saji S, Gupta S, Iwata H, Mastura MY, Dent R, Lu YS, Yin Y, Smruti BK, Toyama T, Malwinder S, Lee SC, Tseng LM, Kim JH, Kim TY, Suh KJ, Cardoso F, Yoshino T, Douillard JY

Annals of oncology : official journal of the European Society for Medical Oncology   31 ( 4 )   451 - 469   2020.4（ ISSN:09237534 ）

Pertuzumab, Trastuzumab, and Docetaxel for HER2-positive Metastatic Breast Cancer (CLEOPATRA): End-Of-Study Results From a Double-Blind, Randomised, Placebo-Controlled, Phase 3 Study

Swain SM, Miles D, Kim SB, Im YH, Im SA, Semiglazov V, Ciruelos E, Schneeweiss A, Loi S, Monturus E, Clark E, Knott A, Restuccia E, Benyunes MC, Cortés J; CLEOPATRA study group

Lancet Oncol.   21 ( 4 )   519 - 530   2020.4

Breast Cancer Provider Interval Length in Fukushima, Japan, After the 2011 Triple Disaster: A Long-Term Retrospective Study.

Ozaki A, Nomura S, Leppold C, Tsubokura M, Sawano T, Tsukada M, Morita T, Tanimoto T, Saji S, Kato S, Yamaoka K, Nakata Y, Ohira H

Clinical breast cancer   20 ( 2 )   e127 - e150   2020.4（ ISSN:1526-8209 ）

CYP2D6 Genotype-Guided Tamoxifen Dosing in Hormone Receptor-Positive Metastatic Breast Cancer (TARGET-1): A Randomized, Open-Label, Phase II Study.

Tamura K, Imamura CK, Takano T, Saji S, Yamanaka T, Yonemori K, Takahashi M, Tsurutani J, Nishimura R, Sato K, Kitani A, Ueno NT, Mushiroda T, Kubo M, Fujiwara Y, Tanigawara Y.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology   36 ( 6 )   558 - 566   2020.2（ ISSN:0732-183X ）

The Japanese Breast Cancer Society Clinical Practice Guideline for radiation treatment of breast cancer, 2018 edition.

Yamauchi C, Yoshimura M, Sekiguchi K, Hamamoto Y, Nakajima N, Sanuki N, Ogo E, Oguchi M, Saji S, Iwata H.

Breast Cancer.   27 ( 1 )   9 - 16   2020.1（ ISSN:1340-6868 ）

The Japanese Breast Cancer Society clinical practice guidelines for surgical treatment of breast cancer, 2018 edition.

Inokuchi M, Kutomi G, Kijima Y, Sakai T, Sawaki M, Shien T, Hanamura N, Yano K, Wada N, Saji S, Iwata H.

Breast Cancer.   27 ( 1 )   4 - 8   2020.1（ ISSN:1340-6868 ）

The Japanese Breast Cancer Society Clinical Practice Guidelines for Breast Cancer Screening and Diagnosis, 2018 Edition.

Uematsu T, Nakashima K, Kikuchi M, Kubota K, Suzuki A, Nakano S, Hirokaga K, Yamaguchi K, Saji S, Iwata H.

Breast Cancer.   27 ( 1 )   17 - 24   2020.1（ ISSN:1340-6868 ）

The Japanese Breast Cancer Society Clinical Practice Guidelines, 2018 edition: the tool for shared decision making between doctor and patient.

Iwata H, Saji S, Ikeda M, Inokuchi M, Uematsu T, Toyama T, Horii R, Yamauchi C.

Breast Cancer.   27 ( 1 )   1 - 3   2020.1（ ISSN:1340-6868 ）

Cluster of differentiation 8 and programmed cell death ligand 1 expression in triple-negative breast cancer combined with autosomal dominant polycystic kidney disease and tuberous sclerosis complex: a case report.

Gonda K, Akama T, Nakamura T, Hashimoto E, Kyoya N, Rokkaku Y, Maejima Y, Horita S, Tachibana K, Abe N, Ohtake T, Shimomura K, Kono K, Saji S, Takenoshita S, Higashihara E

Journal of medical case reports   13 ( 1 )   381   2019.12

【新しい抗体薬;ADC】乳がんに対するADC

名取 穣, 佐治 重衡

がん分子標的治療   17 ( 2 )   128 - 132   2019.12（ ISSN:1347-6955 ）

Characteristics of adverse events of endocrine therapies among older patients with breast cancer.

Honma N, Makita M, Saji S, Mikami T, Ogata H, Horii R, Akiyama F, Iwase T, Ohno S

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer   27 ( 10 )   3813 - 3822   2019.10（ ISSN:0941-4355 ）

Distinct gene expression profiles between primary breast cancers and brain metastases from pair-matched samples.

Iwamoto T, Niikura N, Ogiya R, Yasojima H, Watanabe KI, Kanbayashi C, Tsuneizumi M, Matsui A, Fujisawa T, Iwasa T, Shien T, Saji S, Masuda N, Iwata H

Scientific reports   9 ( 1 )   13343-1 - 13343-8   2019.9

Neoadjuvant exemestane or exemestane plus docetaxel and cyclophosphamide tailored by clinicopathological response to 12 weeks' exemestane exposure in patients with estrogen receptor-positive breast cancer: A multicenter, open-label, phase II study.

Sato N, Masuda N, Morimoto T, Ueno T, Kanbayashi C, Kaneko K, Yasojima H, Saji S, Sasano H, Morita S, Ohno S, Toi M.

Cancer medicine   8 ( 12 )   5468 - 5481   2019.9

【エストロゲン受容体陽性転移乳癌の薬物療法】CDK4/6阻害薬

徳田 恵美, 佐治 重衡

日本内分泌外科学会誌   36 ( 2 )   101 - 106   2019.6

【医薬品副作用学(第3版)上-薬剤の安全使用アップデート-】薬効群別副作用 抗がん薬ホルモン療法薬(乳癌・前立腺癌・子宮体癌のホルモン療法薬)

名取 穣, 佐治 重衡

日本臨床   77 ( 増刊 3 )   94 - 99   2019.6

MLH1 germline mutation associated with Lynch syndrome in a family followed for more than 45 years.

Momma T, Gonda K, Akama Y, Endo E, Ujiie D, Fujita S, Maejima Y, Horita S, Shimomura K, Saji S, Kono K, Yashima R, Watanabe F, Sugano K, Nomizu T

BMC medical genetics   20 ( 1 )   67 - 67   2019.5

誌上ディベート　40歳以上の閉経前ホルモン受容体陽性乳癌患者の術後ホルモン治療にLHRH-Aは併用すべきか「すべきである」とする立場から

阿左見 祐介, 佐治 重衡

Cancer Board of the Breast   5 ( 1 )   40 - 45   2019.3（ ISSN:2189-356X ）

誌上ディベート 40歳以上の閉経前ホルモン受容体陽性乳癌患者の術後ホルモン治療にLHRH-Aは併用すべきか「すべきである」とする立場から

阿左見 祐介, 佐治 重衡

Cancer Board of the Breast   5 ( 1 )   40 - 45   2019.3（ ISSN:2189-356X ）

Changes in Recurrence Score by neoadjuvant endocrine therapy of breast cancer and their prognostic implication.

Ueno T, Saji S, Masuda N, Iwata H, Kuroi K, Sato N, Takei H, Yamamoto Y, Ohno S, Yamashita H, Hisamatsu K, Aogi K, Sasano H, Toi M

ESMO open   4 ( 1 )   e000476   2019.2（ ISSN:2059-7029 ）

Differential Involvement of Autophagy and Apoptosis in Response to Chemoendocrine and Endocrine Therapy in Breast Cancer: JBCRG-07TR.

Ueno T, Masuda N, Kamigaki S, Morimoto T, Saji S, Imoto S, Sasano H, Toi M

International journal of molecular sciences   20 ( 4 )   E984-1 - E984-13   2019.2（ ISSN:16616596 ）

Long isoform of VEGF stimulates cell migration of breast cancer by filopodia formation via NRP1/ARHGAP17/Cdc42 regulatory network.

Kiso M, Tanaka S, Saji S, Toi M, Sato F

International journal of cancer   143 ( 11 )   2905 - 2918   2018.12（ ISSN:0020-7136 ）

Progesterone receptor expression in proliferating cancer cells of hormone-receptor-positive breast cancer.

Ueno T, Saji S, Chiba T, Kamma H, Isaka H, Itoh H, Imi K, Miyamoto K, Tada M, Sasano H, Toi M, Imoto S

Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine   40 ( 10 )   1 - 10   2018.11（ ISSN:1010-4283 ）

Estradiol promotes rapid degradation of HER3 in ER-positive breast cancer cell line MCF-7.

Suga J, Izumiyama K, Tanaka N, Saji S

Biochemistry and biophysics reports   16   103 - 109   2018.10

Poland syndrome accompanied by internal iliac artery supply disruption sequence: a case report.

Gonda K, Tachiya Y, Hatakeyama Y, Momma T, Tamaoki T, Maejima Y, Rokkaku Y, Saji S, Shimomura K, Kono K

Journal of medical case reports   12 ( 1 )   312   2018.10

A case of recurrent colon cancer with peritoneal dissemination treated with aflibercept showing partial response for one year

Gonda K., Fujita S., Shibata M., Hatakeyama Y., Tachiya Y., Rokkaku Y., Saze Z., Momma T., Ohki S., Saji S., Kono K.

Japanese Journal of Cancer and Chemotherapy   45 ( 10 )   1539 - 1542   2018.10（ ISSN:03850684 ）

A randomized, open-label, Phase III trial of pertuzumab retreatment in HER2-positive locally advanced/metastatic breast cancer patients previously treated with pertuzumab, trastuzumab and chemotherapy: the Japan Breast Cancer Research Group-M05 PRECIOUS study.

Yamamoto Y, Iwata H, Ueno T, Taira N, Kashiwaba M, Takahashi M, Tada H, Tsugawa K, Toyama T, Niikura N, Hara F, Fujisawa T, Yoshinami T, Saji S, Takano T, Masuda N, Morita S, Toi M, Ohno S

Japanese journal of clinical oncology   48 ( 9 )   855 - 859   2018.9（ ISSN:0368-2811 ）

Development of a prognostic nomogram for metastatic colorectal cancer patients: The study protocol of a multicenter, retrospective, observational, cohort study

Kawamura H., Honda M., Takiguchi K., Kamiga T., Saito K., Yamazaki S., Muto A., Shiraso S., Yamashita N., Iwao T., Saji S., Kono K.

Annals of Cancer Research and Therapy   26 ( 2 )   116 - 119   2018.8（ ISSN:13446835 ）

The long and winding road for overcoming resistance to hormone therapy in breast cancer.

Saji S

Breast cancer   25 ( 4 )   377 - 378   2018.7（ ISSN:1340-6868 ）

Neoadjuvant endocrine therapy with exemestane followed by response-guided combination therapy with low-dose cyclophosphamide in postmenopausal patients with estrogen receptor-positive breast cancer: A multicenter, open-label, phase II study.

Sato N, Masuda N, Morimoto T, Ueno T, Kanbayashi C, Kaneko K, Yasojima H, Saji S, Sasano H, Morita S, Ohno S, Toi M

Cancer medicine   7 ( 7 )   3044 - 3056   2018.7

Impact of physiological hormonal fluctuations on 18F-fluorodeoxyglucose uptake in breast cancer.

Miyake KK, Nakamoto Y, Saji S, Sugie T, Kurihara K, Kanao S, Ikeda DM, Toi M, Togashi K

Breast cancer research and treatment   169 ( 3 )   437 - 446   2018.6（ ISSN:0167-6806 ）

【明日を拓く乳がん診療-新たなチームアプローチ】 チームで支える乳がんの内分泌療法

佐治 重衡

日本医師会雑誌   147 ( 3 )   495 - 499   2018.6（ ISSN:0021-4493 ）

【乳癌-診断・治療の最新知見-】 乳癌の治療　乳癌の薬物療法　内分泌療法　内分泌療法と分子標的薬の併用

村上 祐子, 立花 和之進, 大竹 徹, 佐治 重衡

日本臨床   76 ( 5 )   760 - 767   2018.5（ ISSN:0047-1852 ）

Regional differences in advanced gastric cancer: exploratory analyses of the AVAGAST placebo arm.

Sawaki Akira, Yamada Yasuhide, Yamaguchi Kensei, Nishina Tomohiro, Doi Toshihiko, Satoh Taroh, Chin Keisho, Boku Narikazu, Omuro Yasushi, Komatsu Yoshito, Hamamoto Yasuo, Koizumi Wasaburo, Saji Shigehira, Shah Manish A., Van Cutsem Eric, Kang Yoon-Koo, Iwasaki Junko, Kuriki Hiroshi, Ohtsuka Wataru, Ohtsu Atsushi

Gastric Cancer   21 ( 3 )   429 - 438   2018.5（ ISSN:1436-3291 ）

The relationship between serum E2 levels and recurrence in premenopausal, ER-positive breast cancer patients: A retrospective study.

Takuwa H, Saji S, Takada M, Takahara S, Yamauchi A

Breast disease   37 ( 4 )   185 - 190   2018.3（ ISSN:0888-6008 ）

Impact of clinical response to neoadjuvant endocrine therapy on patient outcomes: a follow-up study of JFMC34-0601 multicentre prospective neoadjuvant endocrine trial.

Ueno T, Saji S, Masuda N, Kuroi K, Sato N, Takei H, Yamamoto Y, Ohno S, Yamashita H, Hisamatsu K, Aogi K, Iwata H, Yamanaka T, Sasano H, Toi M

3 ( 2 )   e000314   2018.2

Factors Associated With Prolonged Time to Treatment Failure With Fulvestrant 500 Mg in Patients With Post-Menopausal Estrogen Receptor-Positive Advanced Breast Cancer: A Sub-Group Analysis of the JBCRG-C06 Safari Study

Kawaguchi H, Masuda N, Nakayama T, Aogi K, Anan K, Ito Y, Ohtani S, Sato N, Saji S, Takano T, Tokunaga E, Nakamura S, Hasegawa Y, Hattori M, Fujisawa T, Morita S, Yamaguchi M, Yamashita H, Yamashita T, Yamamoto Y, Yotsumoto D, Toi M, Ohno S.

Curr Med Res Opin.   34 ( 1 )   49 - 54   2018.1

A Case of Squamous Cell Carcinoma of Unknown Primary that Responded to the Multi-Tyrosine Kinase Inhibitor Lenvatinib.

Kimura-Tsuchiya R, Sasaki E, Nakamura I, Suzuki S, Kawana S, Okouchi C, Fukushima T, Hashimoto Y, Suzuki S, Saji S

Case reports in oncology   11 ( 1 )   75 - 80   2018.1

Durable complete response in HER2-positive breast cancer: a multicenter retrospective analysis.

Niikura N, Shimomura A, Fukatsu Y, Sawaki M, Ogiya R, Yasojima H, Fujisawa T, Yamamoto M, Tsuneizumi M, Kitani A, Watanabe J, Matsui A, Takahashi Y, Takashima S, Shien T, Tamura K, Saji S, Masuda N, Tokuda Y, Iwata H

Breast cancer research and treatment   167 ( 1 )   81 - 87   2018.1（ ISSN:0167-6806 ）

【がん転移学(下)-がん転移のメカニズムと治療戦略:その基礎と臨床-】 再発転移抑制のための周術期治療　乳癌

木村 礼子, 佐々木 栄作, 野地 秀義, 佐治 重衡

日本臨床   75 ( 増刊9 )   27 - 31   2017.12（ ISSN:0047-1852 ）

A phase I/II pharmacokinetics/pharmacodynamics study of irinotecan combined with S-1 for recurrent/metastatic breast cancer in patients with selected UGT1A1 genotypes (the JBCRG-M01 study).

Ishiguro H, Saji S, Nomura S, Tanaka S, Ueno T, Onoue M, Iwata H, Yamanaka T, Sasaki Y, Toi M

Cancer medicine   6 ( 12 )   2909 - 2917   2017.12

Comparison of immune microenvironments between primary tumors and brain metastases in patients with breast cancer.

Ogiya R, Niikura N, Kumaki N, Yasojima H, Iwasa T, Kanbayashi C, Oshitanai R, Tsuneizumi M, Watanabe KI, Matsui A, Fujisawa T, Saji S, Masuda N, Tokuda Y, Iwata H

Oncotarget   8 ( 61 )   103671 - 103681   2017.11

【がん診療-内科医が知りたい30のエッセンス】内科医が知りたい主ながん種の知識　診断から治療まで　乳がん 再発・転移乳がんの診断・治療について教えてください

佐治 重衡

Medicina   54 ( 8 )   1246 - 1249   2017.7（ ISSN:0025-7699 ）

Breast cancer patient delay in Fukushima, Japan following the 2011 triple disaster: a long-term retrospective study.

Ozaki A, Nomura S, Leppold C, Tsubokura M, Tanimoto T, Yokota T, Saji S, Sawano T, Tsukada M, Morita T, Ochi S, Kato S, Kami M, Nemoto T, Kanazawa Y, Ohira H

BMC cancer   17 ( 1 )   423   2017.6

Outcomes of fulvestrant therapy among japanese women with advanced breast cancer: a retrospective multicenter cohort study (JBCRG-C06; Safari)

Kawaguchi H., Masuda N., Nakayama T., Aogi K., Anan K., Ito Y., Ohtani S., Sato N., Saji S., Tokunaga E., Nakamura S., Hasegawa Y., Hattori M., Fujisawa T., Morita S., Yamaguchi M., Yamashita T., Yamamoto Y., Ohno S., Toi M.

Breast Cancer Research and Treatment   163 ( 3 )   545 - 554   2017.6（ ISSN:01676806 ）

【黄体ホルモンup to date】 乳腺疾患と黄体ホルモン

阿部 宣子, 佐治 重衡, 阿部 貞彦, 野田 勝, 岡野 舞子, 立花 和之進, 吉田 清香, 大竹 徹

産婦人科の実際   66 ( 5 )   619 - 624   2017.5（ ISSN:0558-4728 ）

Estrogen-Related Factors in the Frontal Lobe of Alzheimer's Disease Patients and Importance of Body Mass Index.

Honma N, Saji S, Mikami T, Yoshimura N, Mori S, Saito Y, Murayama S, Harada N

Scientific reports   7 ( 1 )   726   2017.4

【乳癌のすべて】 診断・治療の進歩　再発luminal type乳癌に対するあらたな治療戦略

立花 和之進, 大竹 徹, 佐治 重衡

医学のあゆみ   261 ( 5 )   473 - 477   2017.4（ ISSN:0039-2359 ）

【乳癌学-最新の診断と治療-】 乳癌の治療　乳癌の薬物療法と支持療法　内分泌療法　内分泌療法と分子標的治療薬との併用

佐治 重衡, 木村 礼子, 佐々木 栄作, 野地 秀義

日本臨床   75 ( 増刊3 )   326 - 331   2017.4（ ISSN:0047-1852 ）

Circulating cell-free DNA-based epigenetic assay can detect early breast cancer.

Uehiro N, Sato F, Pu F, Tanaka S, Kawashima M, Kawaguchi K, Sugimoto M, Saji S, Toi M

Breast cancer research : BCR   18 ( 1 )   129   2016.12（ ISSN:1465-5411 ）

Breast and Endocrine Tumor

43 ( 13 )   2509 - 2512   2016.12（ ISSN:0385-0684 ）

【乳がんに対する新しい診断技術と治療戦略】 ホルモン抵抗性乳がんに対する内分泌療法と分子標的薬との併用

鹿目 将至, 佐治 重衡

腫瘍内科   18 ( 3 )   214 - 219   2016.9（ ISSN:1881-6568 ）

【乳癌発症リスクとその対策】 女性ホルモンと乳癌

阿部 宣子, 大竹 徹, 佐治 重衡

乳癌の臨床   31 ( 3 )   187 - 192   2016.6（ ISSN:0911-2251 ）

Social isolation and cancer management after the 2011 triple disaster in Fukushima, Japan: A case report of breast cancer with patient and provider delay.

Ozaki A, Leppold C, Tsubokura M, Tanimoto T, Saji S, Kato S, Kami M, Tsukada M, Ohira H

Medicine   95 ( 26 )   e4027   2016.6（ ISSN:0025-7974 ）

【分子標的治療薬の併用療法の可能性(一部臨床試験ベース)】 乳癌に対する分子標的治療薬の併用療法の可能性

岡野 舞子, 大竹 徹, 佐治 重衡

癌と化学療法   43 ( 4 )   398 - 403   2016.4（ ISSN:0385-0684 ）

Clinical significance of the expression of autophagy-associated marker, beclin 1, in breast cancer patients who received neoadjuvant endocrine therapy.

Ueno T, Saji S, Sugimoto M, Masuda N, Kuroi K, Sato N, Takei H, Yamamoto Y, Ohno S, Yamashita H, Hisamatsu K, Aogi K, Iwata H, Imoto S, Sasano H, Toi M.

BMC Cancer.   16 ( 1 )   230   2016.3

Joint symptoms and health-related quality of life in postmenopausal women with breast cancer who completed 5 years of anastrozole.

Yagata H, Ohtsu H, Komoike Y, Saji S, Takei H, Nakamura T, Ohashi Y, Iwase T, Shimozuma K.

Support Care Cancer.   24 ( 2 )   683 - 689   2016.2

One-point Lesson(第1回)　スライドの作り方

佐治 重衡

2 ( 1 )   69 - 71   2016.2（ ISSN:2189-356X ）

Molecular diagnostics for precision medicine in breast cancer treatment: what does the future hold?

Saji S, Kimura-Tsuchiya R, Sasaki E

Breast cancer (Tokyo, Japan)   23 ( 1 )   1 - 3   2016.1（ ISSN:1340-6868 ）

Genomic tumor evolution of breast cancer.

Sato F, Saji S, Toi M

Breast cancer (Tokyo, Japan)   23 ( 1 )   4 - 11   2016.1（ ISSN:1340-6868 ）

Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer .

Ozaki A, Tanimoto T, Saji S.

N Engl J Med   373 ( 17 )   1672 - 1673   2015.10

Differences in clinical importance of Bcl-2 in breast cancer according to hormone receptors status or adjuvant endocrine therapy.

Honma N, Horii R, Ito Y, Saji S, Younes M, Iwase T, Akiyama F

BMC cancer   15 ( 1 )   698   2015.10

Intensive vs. Standard Post-Operative Surveillance in High-Risk Breast Cancer Patients (INSPIRE): Japan Clinical Oncology Group Study JCOG1204.

Hojo T, Masuda N, Mizutani T, Shibata T, Kinoshita T, Tamura K, Hara F, Fujisawa T, Inoue K, Saji S, Nakamura K, Fukuda H, Iwata H

Japanese journal of clinical oncology   45 ( 10 )   983 - 986   2015.10（ ISSN:0368-2811 ）

抗体治療の新展開

大津 敦, 赤司 浩一, 佐治 重衡, 吉村 清

がん分子標的治療   13 ( 2 )   224 - 231   2015.7（ ISSN:1347-6955 ）

Clinicopathological characteristics of breast cancer and trends in the management of breast cancer patients in Japan: Based on the Breast Cancer Registry of the Japanese Breast Cancer Society between 2004 and 2011

Kurebayashi J., Miyoshi Y., Ishikawa T., Saji S., Sugie T., Suzuki T., Takahashi S., Nozaki M., Yamashita H., Tokuda Y., Nakamura S.

Breast Cancer   22 ( 3 )   235 - 244   2015.5（ ISSN:13406868 ）

【生活習慣からみたがん発生・予防】 やせ・肥満と乳がん発生リスク　女性のライフステージ別に異なる可能性について

鈴木 礼子, 佐治 重衡

癌と化学療法   42 ( 5 )   525 - 528   2015.5（ ISSN:0385-0684 ）

【早期乳がんおよび進行乳がんに対する新しい標準治療の開発】 閉経前ホルモン受容体陽性早期乳がんに対する術後内分泌療法

山口 絢音, 佐治 重衡, 戸井 雅和

腫瘍内科   15 ( 5 )   438 - 443   2015.5（ ISSN:1881-6568 ）

Combination of molecular-targeted drugs with endocrine therapy for hormone-resistant breast cancer.

Saji S, Kimura-Tsuchiya R

International journal of clinical oncology   20 ( 2 )   268 - 72   2015.4（ ISSN:1341-9625 ）

【ますます臨床利用が進む遺伝子検査-その現状と今後の展開そして課題-】 (第2章)分子標的治療のための体細胞遺伝子検査の現況　乳がん

佐藤 史顕, 佐治 重衡, 戸井 雅和

遺伝子医学MOOK   ( 28 )   81 - 86   2015.4（ ISSN:1349-2527 ）

Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer.

Swain SM, Baselga J, Kim SB, Ro J, Semiglazov V, Campone M, Ciruelos E, Ferrero JM, Schneeweiss A, Heeson S, Clark E, Ross G, Benyunes MC, Cortés J; CLEOPATRA Study Group.

N Engl J Med.   372 ( 8 )   724 - 734   2015.2

Development of breast cancer therapy: biomarker-driven and response-guided approaches in a neoadjuvant setting.

Toi M, Masuda N, Ishiguro H, Saji S, Ohno S, Chow LW.

Int J Biol Markers.   30 ( 2 )   252 - 253   2015.2

【抗がん剤の副作用と支持療法-より適切な抗がん剤の安全使用をめざして-】 系統別抗がん剤の副作用　内分泌療法薬　内分泌療法薬の作用機序と副作用　概論

津田 萌, 石黒 洋, 佐治 重衡

日本臨床   73 ( 増刊2 )   291 - 297   2015.2（ ISSN:0047-1852 ）

【分子標的薬耐性メカニズムと対策】 乳癌に対するHER2阻害薬療法耐性の機序と展望

河口 浩介, 鈴木 栄治, 佐治 重衡

医学のあゆみ   252 ( 7 )   809 - 813   2015.2（ ISSN:0039-2359 ）

Prognostic factors of HER2-positive breast cancer patients who develop brain metastasis: a multicenter retrospective analysis.

Hayashi N, Niikura N, Masuda N, Takashima S, Nakamura R, Watanabe K, Kanbayashi C, Ishida M, Hozumi Y, Tsuneizumi M, Kondo N, Naito Y, Honda Y, Matsui A, Fujisawa T, Oshitanai R, Yasojima H, Yamauchi H, Saji S, Iwata H.

Breast Cancer Res Treat.   149 ( 1 )   277 - 284   2015.1

Ki-67 evaluation at the hottest spot predicts clinical outcome of patients with hormone receptor-positive/HER2-negative breast cancer treated with adjuvant tamoxifen monotherapy

Honma Naoko, Horii Rie, Iwase Takuji, Saji Shigehira, Younes Mamoun, Ito Yoshinori, Akiyama Futoshi

Breast cancer   22 ( 1 )   71 - 78   2015.1（ ISSN:1340-6868 ）

総説論文というもの（エッセイ）

佐治重衡.

日本癌病態治療研究会誌.   21 ( 1 )   47 - 48   2015

Proportion of estrogen or progesterone receptor expressing cells in breast cancers and response to endocrine therapy.

Honma N,Horii R,Iwase T,Saji S,Younes M,Ito Y,Akiyama F.

Breast   23 ( 6 )   754 - 762   2014.12

ホルモン受容体陽性乳がんに対するタモキシフェン治療とCYP2D6遺伝子多型

今村 知世, 佐治 重衡

がん分子標的治療   12 ( 4 )   449 - 455   2014.12（ ISSN:1347-6955 ）

【外科領域のpros and cons】 閉経前,腋窩リンパ節転移陽性,luminal A乳癌の治療　術前薬物療法

佐治 重衡, 木村 礼子

外科   76 ( 13 )   1550 - 1553   2014.12（ ISSN:0016-593X ）

【ステロイドホルモンと骨-基礎から臨床まで】 性ステロイドと骨代謝　乳癌患者におけるアロマターゼ阻害薬と骨粗鬆症

林 直輝, 山内 英子, 佐治 重衡

THE BONE   28 ( 4 )   429 - 434   2014.12（ ISSN:0914-7047 ）

State of the ART　Genetic tumor evolution

7 ( 2 )   119 - 126   2014.12（ ISSN:1883-1699 ）

On going clinical study JBCRG-M04 BOOSTER試験(ホルモン陽性HER2陰性進行再発乳癌に対する、ホルモン療法による維持療法を利用したベバシズマブ+パクリタキセル療法の治療最適化研究)

佐治 重衡

Cancer Board 乳癌   7 ( 2 )   168 - 169   2014.12（ ISSN:1883-1699 ）

Brain metastases in breast cancer.

Niikura N, Saji S, Tokuda Y, Iwata H

Japanese journal of clinical oncology   44 ( 12 )   1133 - 40   2014.10（ ISSN:0368-2811 ）

Necrostatin-1 protects against reactive oxygen species (ROS)-induced hepatotoxicity in acetaminophen-induced acute liver failure.

Takemoto K, Hatano E, Iwaisako K, Takeiri M, Noma N, Ohmae S, Toriguchi K, Tanabe K, Tanaka H, Seo S, Taura K, Machida K, Takeda N, Saji S, Uemoto S, Asagiri M.

FEBS Open Bio.   777 - 87   2014.9

抗HER2療法の新時代　ALTTO試験の結果から

清水華子、諏訪裕文、佐治重衡

腫瘍内科   14 ( 3 )   268 - 272   2014.9

Treatment outcomes and prognostic factors for patients with brain metastases from breast cancer of each subtype:a multicenter retrospective analysis.

Niikura N,Hayashi N,Masuda N,Takashima S,Nakamura R,Watanabe KI,Kanbayashi C,Ishida M,Hozumi Y,Tsuneizumi M, Kondo N,Naito Y,Honda Y,Matsui A,Fujisawa T,Oshitanai R, Yasojima H,Tokuda Y,Saji S, Iwata H.

Breast Cancer Res Treat   147 ( 1 )   103 - 112   2014.8

Evaluating the 21-gene assay Recurrence Score as a predictor of clinical response to 24 weeks of neoadjuvant exemestane in estrogen receptor-positive breast cancer

Ueno Takayuki, Masuda Norikazu, Yamanaka Takeharu, Saji Shigehira, Kuroi Katsumasa, Sato Nobuaki, Takei Hiroyuki, Yamamoto Yutaka, Ohno Shinji, Yamashita Hiroko, Hisamatsu Kazufumi, Aogi Kenjiro, Iwata Hiroji, Sasano Hironobu, Toi Masakazu

International Journal of Clinical Oncology   19 ( 4 )   607 - 613   2014.8（ ISSN:1341-9625 ）

【分子標的治療に対する自然耐性と獲得耐性とその克服】 乳がんの抗HER2療法耐性機序とその克服

河口 浩介, 鈴木 栄治, 佐治 重衡

がん分子標的治療   12 ( 2 )   129 - 135   2014.6（ ISSN:1347-6955 ）

【コンパニオン診断-診断薬開発から臨床応用へ】 乳癌におけるコンパニオン診断

佐藤 史顕, 佐治 重衡, 三上 芳喜

医学のあゆみ   248 ( 11 )   845 - 850   2014.3（ ISSN:0039-2359 ）

【血管新生阻害薬の展開】 乳がんにおける血管新生の制御

木曾 末厘乃, 佐治 重衡, 戸井 雅和

最新医学   68 ( 12 )   2665 - 2671   2013.12（ ISSN:0370-8241 ）

【がんの分子標的治療:進歩と課題】 トラスツズマブ耐性乳癌における抗Her2療法

森 由希子, 佐治 重衡

31 ( 11 )   31 - 35   2013.11（ ISSN:0289-5803 ）

【HER2陽性乳癌の治療戦略】 HER2陽性転移性乳癌の治療方針

植弘 奈津恵, 佐治 重衡

乳癌の臨床   28 ( 5 )   511 - 518   2013.10（ ISSN:0911-2251 ）

Clinical importance of androgen receptor in breast cancer patients treated with adjuvant tamoxifen monotherapy

Honma Naoko, Horii Rie, Iwase Takuji, Saji Shigehira, Younes Mamoun, Ito Yoshinori, Akiyama Futoshi

Breast Cancer   20 ( 4 )   323 - 330   2013.10（ ISSN:1340-6868 ）

【乳がん】 エリブリン最新情報

佐治 重衡

クリニシアン   60 ( 10 )   895 - 902   2013.10（ ISSN:0387-1541 ）

Concomitant polypharmacy is associated with irinotecan-related adverse drug reactions in patients with cancer

Sasaki Tetsuya, Fujita Ken-ichi, Sunakawa Yu, Ishida Hiroo, Yamashita Keishi, Miwa Keisuke, Saji Shigehira, Kato Yasuhisa, Sasaki Yasutsuna

International Journal of Clinical Oncology   18 ( 4 )   735 - 742   2013.8（ ISSN:1341-9625 ）

A phase II study of lapatinib for brain metastases in patients with HER2-overexpressing breast cancer following trastuzumab based systemic therapy and cranial radiotherapy: subset analysis of Japanese patients

Iwata Hiroji, Narabayashi Masaru, Ito Yoshinori, Saji Shigehira, Fujiwara Yasuhiro, Usami Shigeyuki, Katsura Koichi, Sasaki Yasutsuna

International Journal of Clinical Oncology   18 ( 4 )   621 - 628   2013.8（ ISSN:1341-9625 ）

【乳がんのすべて】 (PART.4)乳がんの治療　薬物療法　ホルモン療法の治療戦略

光藤 悠子, 佐治 重衡

からだの科学   ( 277 )   67 - 71   2013.5（ ISSN:0453-3038 ）

Efficacy and safety of capecitabine plus cisplatin in Japanese patients with advanced or metastatic gastric cancer: subset analyses of the AVAGAST study and the ToGA study

Yamaguchi Kensei, Sawaki Akira, Doi Toshihiko, Satoh Taroh, Yamada Yasuhide, Omuro Yasushi, Nishina Tomohiro, Boku Narikazu, Chin Keisho, Hamamoto Yasuo, Takiuchi Hiroya, Komatsu Yoshito, Saji Shigehira, Koizumi Wasaburo, Miyata Yoshinori, Sato Atsushi, Baba Eishi, Tamura Takao, Abe Takashi, Ohtsu Atsushi

Gastric Cancer   16 ( 2 )   175 - 182   2013.4（ ISSN:1436-3291 ）

乳癌薬物療法の要点と盲点

戸井雅（監）、佐治重衡・増田慎三（編）（乳癌薬物療法の要点と盲点）

文光堂  2023.6  （ ISBN:978-4-8306-2264-9 ）

乳癌薬物療法の要点と盲点

戸井雅（監）、佐治重衡・増田慎三（編）（Ⅰ基本事項１.基本アルゴリズムの理解のしかた　ｂ.進行・再発期治療）

文光堂  2023.6  （ ISBN:978-4-8306-2264-9 ）

CANCER BOARD of the BREAST 7(2)

戸井雅和（The review of clinical study　JBCRG-ABCD　project）

メディカルレビュー社  2023.5 

改訂4版　2ページで理解する標準薬物治療ファイル

日本アプライド・セラピューティクス学会（53.初期乳癌）

南山堂  2023.3 

改訂4版　2ページで理解する標準薬物治療ファイル

日本アプライド・セラピューティクス学会（54.転移・再発乳癌）

南山堂  2023.3 

患者さんのための乳がん診療ガイドライン　2023年版

日本乳癌学会（患者さんのための乳がん診療ガイドライン　2023年版）

金原出版  2023.2  （ ISBN:9784307204484 ）

治療戦略に役立つ臨床医病理医のための乳腺病理の見かた考え方

増田慎三・堀井理絵（Ⅳ Biology評価 ： Ki67の臨床的意義）

メジカルビュー社  2022.11  （ ISBN:978-4-7583-1817-4 ）

乳癌診療state of the art 科学に基づく最新診療

戸井雅和（第18章 ホルモン療法 1. ホルモン療法薬の分類と新たな薬剤クラス）

医歯薬出版株式会社  2022.9  （ ISBN:978-4-263-73205-2 ）

乳癌診療ガイドライン　①治療編　2022年版

日本乳癌学会

金原出版  2022.6  （ ISBN:978-4-307-20441-5 ）

乳癌診療ガイドライン　②疫学・診断編 2022年版

日本乳癌学会

金原出版  2022.6  （ ISBN:978-4-307-20442-2 ）

がんがみえる 第1版　

医療情報科学研究所（乳房のがん）

メディックメディア  2022.2  （ ISBN:978-4-89632-860-8 ）

アプローチと実践がわかる　高齢者の乳がん診療

日本臨床腫瘍学会（アプローチと実践がわかる　高齢者の乳がん診療）

南江堂  2021.2  （ ISBN:978-4-524-22807-2 ）

入門腫瘍内科学　改訂第３版

日本臨床腫瘍学会

南江堂  2020 

入門腫瘍内科学　改訂第３版

日本臨床腫瘍学会（6.がん薬物療法　D内分泌療法）

南江堂  2020 

乳腺腫瘍学　第3版

日本乳癌学会（４ 術後内分泌療法）

金原出版  2020 

乳腺腫瘍学 第3版

日本乳癌学会（４ 術後内分泌療法）

金原出版  2020 

入門腫瘍内科学 改訂第３版

日本臨床腫瘍学会（6.がん薬物療法 D内分泌療法）

南江堂  2020 

患者さんのための乳がん診療ガイドライン　2019年版

日本乳癌学会

金原出版  2019 

乳がん薬物療法ハンドブック

南江堂  2019 

がん治療エッセンシャルガイド　改訂4版

佐藤隆美、藤原康弘、古瀬純司、大山優（乳がんの薬物療法）

南山堂  2019 

がん治療エッセンシャルガイド 改訂4版

佐藤隆美, 藤原康弘, 古瀬純司, 大山優（乳がんの薬物療法）

南山堂  2019 

新臨床腫瘍学－がん薬物療法専門医のために－(改訂第5版)

日本臨床腫瘍学会

南江堂  2018.7 

乳癌診療ガイドライン　①治療編　2018年版

日本乳癌学会

金原出版  2018.5 

乳癌診療ガイドライン ②疫学・診断編 2018年版

日本乳癌学会

金原出版  2018.5 

エビデンスに基づいた癌化学療法ハンドブック 2018

大津敦　総監修（第2章　乳癌　術後・転移・再発：Tamoxifen、）

メデイカルレビュー社  2018 

エビデンスに基づいた癌化学療法ハンドブック 2018

大津敦　総監修（第2章　乳癌　術後・転移・再発： Exemestane、）

メデイカルレビュー社  2018 

エビデンスに基づいた癌化学療法ハンドブック 2018

大津敦　総監修（第2章　乳癌　術後・転移・再発：Tamoxifen + LH-RH agonoist療法、）

メデイカルレビュー社  2018 

エビデンスに基づいた癌化学療法ハンドブック 2018

大津敦　総監修（第2章　乳癌　術後・転移・再発： exemestane+ LHRH agonoist療法、）

メデイカルレビュー社  2018 

乳がん薬物療法副作用マネジメント

増田慎三（進行再発乳がんに対する薬物療法）

メジカルビュー社  2017.9 

乳がん患者ケアパーフェクトブック

阿部恭子、矢形寛（乳がんの治療　内分泌療法）

学研メデイカル秀潤社  2017.8 

これからの乳癌診療2017-2018

園尾博司監修、福田護・池田正・佐伯俊昭・鹿間直人編（分子標的薬の進步 2016〜2017）

金原出版  2017.7 

チームで学ぶ女性がん患者のための　ホルモンマネージメント

佐治重衡・清水千佳子

篠原出版  2017.7 

エビデンスに基づいた癌化学療法ハンドブック 2017

大津敦　総監修（乳癌　術後・転移・再発：Exemestane、tamoxifen + LHRH agonoist療法、exemestane + LHRH agonoist療法）

メデイカルレビュー社  2017 

小児、思春期、若年がん患者の妊孕性温存に関する診療ガイドライン

一般社団法人　日本癌治療学会（乳腺CQ3）

金原出版  2017 

薬が見える　vol.3 第1版

医療情報科学研究所（ホルモン療法薬、乳房のがん）

メディックメディア  2016.11 

オンコロジークリニカルガイド　乳腺薬物療法　改訂2版

木下貴之、戸井雅和（第Ⅱ章　乳癌薬物療法の実際　・分子標的治療④ベバシズマブ　臨床試験と実際の投与方法）

南山堂  2016.11 

乳癌診療のための分子病理エッセンシャル

津田均、他編（ホルモン受容体陽性乳癌に対する治療戦略）

南山堂  2016.7 

乳腺腫瘍学　第2版

日本乳癌学会編（2-2 B.原発乳癌　術後内分泌療法）

金原出版株式会社  2016.4 

EBM がん化学療法・分子標的治療法2016-2017 edition　

西條長宏（監修）朴成和　大江裕一郎　南博信　直江知樹　編（IV.A.2 術後ホルモン療法は何年間が適切か？ 　）

中外医学社  2015.10 

新臨床腫瘍学－がん薬物療法専門医のために－(改訂第４版)

日本臨床腫瘍学会編（22.乳がん）

南江堂  2015.7 

エベロリムスによる乳癌治療の新展開

野口　眞三郎

メディカルレビュー社  2014.6  （ ISBN:978-7792-1231-4 ）

Human leukocyte antigen(HLA) type as a possible predictive marker for thyroid immune-related adverse event

2024.2  

OS results from the PRECIOUS (JBCRG-M05): Pertuzumab retreatment for HER2-positive advanced breast cancer patients

2024.2  

A case of Takotsubo cardiomyopathy during Lenvatinib treatment for papillary thyroid cancer

2024.2  

福島県におけるHBOC診療の現状報告と今後の課題

第31回日本乳癌学会総会   2023.6  

ER陽性/HER陰性進行再発乳癌に対する酢酸メドロキシプロゲ ステロンの有効性に関する検討

第31回日本乳癌学会総会   2023.7  

Treatment patterns, healthcare resource utilization, and outcomes for early stage TNBC in Japan

第31回日本乳癌学会総会   2023.7  

低用量のアルコール摂取習慣が乳癌患者へ及ぼす影響について

第31回日本乳癌学会総会   2023.7  

Updated survival outcomes of the POTENT trial of adjuvant S-1 and endocrine therapy in ER+/HER2- EBC

第31回日本乳癌学会総会   2023.6  

NCD乳癌登録を用いたInvasive lobular carcinomaのサブタイプ別の予後に関する研究

第31回日本乳癌学会総会   2023.6  

日本乳癌学会におけるビッグデータサイエンスの方向性

第31回日本乳癌学会総会   2023.6  

Pembrolizumab投与後に心筋炎を発症した、血管周囲性類上皮細胞腫瘍の1例

第153回東北連合産科婦人科学会総会・学術講演会   2023.6  

大きな変化を迎えたHER2陽性進行再発乳癌の治療戦略

第29回日本乳腺疾患研究会  

Endocrine toxicities associated with Immune Checkpoint Inhibitors in breast cancer patients in our hospital.

2023 the Japanese Society of Medical Oncology Annual Meeting -The 20th Anniversary Meeting-  

usefulness of Urine dipstick test in the management of adverse events associated with immune checkpoint inhibitors.

2023 the Japanese Society of Medical Oncology Annual Meeting -The 20th Anniversary Meeting-  

The usefulness of pre-order medical record checking for the insurance civered Comprehensive Genomic Profiling test.

2023 the Japanese Society of Medical Oncology Annual Meeting -The 20th Anniversary Meeting-  

当施設における乳癌診療の均てん化の試みと課題

第20回日本乳癌学会東北地方会  

Clinical trials in focus：Featured Clinical Trials ④

Best of SABCS 2022 in Kyoto  

周術期治療におけるオラパリブの位置づけ

HER2陰性再発リスクの高い早期乳癌におけるアンスラサイクリン・タキサンの治療実態

第60回日本癌治療学会学術集会  

乳がん内分泌療法中の女性における閉経関連尿路生殖器症候群の実態

第24回日本女性骨盤底医学会  

日本国内における進行・再発乳癌患者レジストリ構築-Advanced Breast Cancer Database プロジェクト

第30回日本乳癌学会総会  

乳癌補助療法における自動投与デバイスによるペグフィルグラ スチム投与の安全性評価試験（第Ⅰ相試験）

第30回日本乳癌学会総会  

日本乳癌学会編 乳癌診療ガイドライン/患者さんのための乳癌診療ガイドラインの役割とその変遷

第65回日本形成外科学会総会・学術総会  

HLA遺伝子型を用いた免疫関連有害事象のナルコレプシー発症のリスク評価

第119回日本内科学会総会  

免疫チェックポイント阻害薬を用いた乳癌術前治療の戦略ポイント

第122回日本外科学会定期学術集会  

乳癌診療ガイドラインから見た乳がん外科領域の臨床試験

第122回日本外科学会定期学術集会  

ＨＲ陽性ＨＥＲ2陰性転移再発乳癌に対するパルボシクリブ投与例の治療成績と次治療について

第19回日本乳癌学会東北地方会  

がんゲノム医療コーディネーター看護師の役割と課題

第36回日本がん看護学会学術集会  

Ubiquitin ligase NEDD4 promotes degradation of estrogen receptor in breast cancer and affects prognosis.

Current status and research issues of late recurrence in breast cancer treatment.

Evaluation of clinical usefulness of cancer genomic profiling tests at the cancer genomic medicine cooperative hospital.

Study for exploring myeloma-initiating cell using normal B cell-derived iPS cells

A Phase 1/2 Study of Patritumab Deruxtecan (HER3-DXd; U3-1402) in Patients with HER3-Expressing MBC

ER発現が低下した内分泌療法耐性乳癌細胞のER発現をPI3K阻害薬が再発現させる機序にエピゲノム変化が関与する

第29回日本乳癌学会総会  

良悪性の鑑別に難渋した乳腺悪性腺筋上皮腫の一例

第29回日本乳癌学会総会  

Incorporation of novel evidence to the Japanese Breast Cancer Society Clinical Practice Guideline and its impact to the treatment decision.

妊娠中に周術期化学療法を行った乳癌患者への多職種連携支援の重要性

第18回日本臨床腫瘍学会学術集会(JSMO2021)  

免疫チェックポイント阻害薬によるナルコレプシー発症のリスク

第18回日本臨床腫瘍学会学術集会(JSMO2021)  

Research for onset mechanism of Multiple Myeloma. Can B cell-derived iPS cells redifferentiate into B cells?

乳癌（初期薬物療法）

第18回日本臨床腫瘍学会学術集会(JSMO2021)  

大学病院外来化学療法センターにおけるCSCA（災害医療実践）を取り入れたCOVID-19対策

第18回日本臨床腫瘍学会学術集会(JSMO2021)  

PRECIOUS: Pertuzumab re-treatment for HER2-positive locally advanced/metastatic breast cancer (JBCRG-M05)

大規模自然災害時のがん診療とがん患者さんへのケア

第18回日本臨床腫瘍学会学術集会(JSMO2021)  

がんゲノム医療時代の進行再発乳がん治療とリムパーザの位置づけ

第18回日本臨床腫瘍学会学術集会(JSMO2021)  

PD12-11(Spotlight Poster Discussion). Patient-reported outcomes from the Phase III IMpassion031 trial of neoadjuvant atezolizumab + chemotherapy in early triple-negative breast cancer.

San Antonio Breast Cancer Symposium 2020  

GS3-04(GENERAL SESSION).　Double-blind placebo (PBO)-controlled randomized phase III trial evaluating first-line ipatasertib (IPAT) combined with paclitaxel (PAC) forPIK3CA/AKT1/PTEN-altered locally advanced unresectable or metastatic triple-negative breast cancer (aTNBC): primary results from IPATunity130 Cohort A.

San Antonio Breast Cancer Symposium 2020  

GS3-02(GENERAL SESSION) . Patient-reported outcomes (PROs) from the Ph 3 IMpassion031 trial of neoadjuvant (NA) atezolizumab + chemo in early triple-negative breast cancer (eTNBC).

San Antonio Breast Cancer Symposium 2020  

PD3-11(Spotlight Poster Discussion). A randomized, open-label, phase III trial of pertuzumab re-treatment in HER2-positive, locally advanced/metastatic breast cancer patients previously treated with pertuzumab, trastuzumab, and chemotherapy: The Japan Breast Cancer Research Group-M05 (PRECIOUS) study.

San Antonio Breast Cancer Symposium 2020  

PS5-06 (Poster Session). Prospective testing for PIK3CA/AKT1/PTEN alterations in tumor tissue from 1440 patients with advanced hormone receptor-positive HER2-negative breast cancer (HR+/HER2- BC) or triple-negative breast cancer (TNBC) screened for the IPATunity130 randomized phase 3 trial.

San Antonio Breast Cancer Symposium 2020  

OT-30-01(Ongoing Trials Posters). KEYLYNK-009: A phase 2/3, open-label, randomized study of pembrolizumab plus olaparib vs pembrolizumab plus chemotherapy after induction with first-line pembrolizumab plus chemotherapy in patients with locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC).

San Antonio Breast Cancer Symposium 2020  

PD1-09(Spotlight Poster Discussion). Safety and efficacy results from the phase 1/2 study of U3-1402, a human epidermal growth factor receptor 3 (HER3)-directed antibody drug conjugate (ADC), in patients with HER3-expressing metastatic breast cancer (MBC).

San Antonio Breast Cancer Symposium 2020  

3MO - IMpassion031: Results from a phase III study of neoadjuvant (neoadj) atezolizumab + chemo in early triple-negative breast cancer (TNBC) (ID 512).

ESMO asia 2020.  

68TiP: KEYLYNK-009:A phase II/III, open-label, randomized study of pembrolizumab (pembro) + olaparib (ola) vs pembro + chemotherapy after induction with first-line (1L) pembro + chemo in patients (pts) with locally recurrent inoperable or metastatic TNBC. (ID 515)

ESMO asia 2020.  

Invited Discussant abstracts 2MO, LBA1, 47MO and 48MO (ID 1072).

ESMO asia 2020.  

乳癌診療の新たな構築2020、

第58回日本癌治療学会学術集会  

Functional analysis of CLDN4

PI3K inhibitors restored the sensitivity to antiestrogen drugs in endocrine therapy resistant cells

Examination of pathological transformation cases after preoperative chemotherapy in breast cancer

Factors associated with prolonged OS in postmenopausal ER-positive advanced breast cancer patients

Clinical results of 30 metastatic breast cancer cases treated with CDK4/6 inhibitor

Influence of the adjuvant endocrine therapy on endocrine sensitivity of the advanced breast cancer

Outcomes of fulvestrant treatment in ER-positive HER2-positive advanced or metastatic breast cancer

Trend in adjuvant therapy after breast-conserving surgery for DCIS using National Clinical Database

乳がん登録を利用した研究の現状と展望

第28回日本乳癌学会総会  

A randomized P2 study evaluating efficacy of maintenance endocrine therapy following PTX+Bev in ABC

Addition of S-1 to adjuvant endocrine therapy for women with hormone receptor-positive breast cancer

Differentiation of blood cells from human fibroblast-derived induced pluripotent stem cells.

Histopathological nuclear grading system for high-risk nodenegativeinvasive breast cancer in the NSAS-BC-01 trial.

The 79th Annual Meeting of the Japanese Cancer Association.  

Prospects of Immunotherapy for Breast Cancer.

The 79th Annual Meeting of the Japanese Cancer Association.  

遠隔転移を伴う大腸癌に対する集学的治療の実際　遠隔臓器切除不能Stage IV大腸癌における原発切除の予後延長効果　多施設共同過去起点コホート研究 WS-9-8

第120回日本外科学会定期学術集会  

乳癌におけるCLDN4発現の分子生物学的検討 DP-016-3

第120回日本外科学会定期学術集会  

NCDデータを用いた本邦における高齢者進行乳癌における局所治療の実態と予後 SF-025-4

第120回日本外科学会定期学術集会  

外来化学療法を受ける患者の心身の状態と看護実践　改訂版問診票の調査より

第34回日本がん看護学会学術集会  

乳癌診療におけるリキッドバイオプシーの将来展望

第４回 liquid biopsy 研究会  

PI3K inhibitors restored the sensitivity to anti-estrogen drugs in endocrine therapy resistant cell lines.

2019 San Antonio Breast Cancer Symposium  

Estimation of willingness-to-pay for breast cancer treatments through contingent valuation method in Japanese breast cancer patients (JCOG1709A).

2019 San Antonio Breast Cancer Symposium  

Outcomes of fulvestrant therapy among Japanese women with ER-positive HER2-positive advanced or metastatic breast cancer: A subgroup analysis of the JBCRG-C06 safari study.

2019 San Antonio Breast Cancer Symposium  

Influence of the adjuvant hormonal therapy on hormone sensitivity and survival outcomes in ER+ and HER2−advanced breast cancer: A subgroup analysis of the JBCRG-C06 Safari study.

2019 San Antonio Breast Cancer Symposium  

Systemic therapy for and prognosis of older stage II and III breast cancer patients: Evaluation of data from the Japanese breast cancer registry.

2019 San Antonio Breast Cancer Symposium  

Factors associated with prolonged post-recurrence survival in patients with postmenopausal estrogen receptor-positive breast cancer taking fulvestrant: A follow-up data of the JBCRG-C06 Safari study

2019 San Antonio Breast Cancer Symposium  

Fulvestrant with additional palbociclib in advanced or metastatic hormone receptor-positive HER2-negative breast cancer after progression to fulvestrant monotherapy: JBCRG- M07 (FUTURE trial).

2019 San Antonio Breast Cancer Symposium  

Pooled analysis of long-term outcome of patients enrolled in two trials comparing the efficacy of oral tegafur-uracil with CMF (N-SAS-BC01 and CUBC trials).

2019 San Antonio Breast Cancer Symposium  

A randomized, multicenter, phase II study evaluating the efficacy of interventional maintenance endocrine therapy with bevacizumab following fixed cycles of bevacizumab plus paclitaxel in advanced/metastatic ER-positive HER2-negative breast cancer: JBCRG-M04 BOOSTER trial.

2019 San Antonio Breast Cancer Symposium  

Phase 1/2 first-in-human study of U3-1402, an anti-human epidermal growth factor receptor 3 (HER3) antibody-drug conjugate, in HER3-expressing advanced/unresectable or metastatic breast cancer, including those with triple negative breast cancer (TNBC) or HER3-low disease.

2019 San Antonio Breast Cancer Symposium  

Addition of S-1 to endocrine therapy in the post-operative adjuvant treatment of hormone receptor-positive and human epidermal growth factor receptor 2-negative primary breast cancer: A multicenter, open-label, phase 3 randomized trial (POTENT trial)

2019 San Antonio Breast Cancer Symposium  

ステージIV期大腸癌における、原発占拠部位と転移様式、予後の関連　O29-3

第57回日本癌治療学会学術集会  

耐性を考慮した乳癌治療戦略　耐性機序を想定した乳癌ホルモン療法(英語)　SY12-2

第57回日本癌治療学会学術集会  

チームオンコロジーワークショップの職種別課題　P50-5

第57回日本癌治療学会学術集会  

結腸・直腸癌に対するFOLFIRI+Aflibercept療法を施行した10例の治療成績　P20-3

第57回日本癌治療学会学術集会  

Elderly patients in the Japanese breast cancer registry.

European Society of Medical Oncology 2019 Congress  

Estradiol regulates half life time of HER3 protein in ER-positive breast cancer

CDK4/6阻害剤耐性となった各種内分泌療法耐性乳癌細胞の細胞内リン酸化シグナルの変化と阻害剤耐性獲得後に有効な薬剤についての検討 P3-114

第17回日本臨床腫瘍学会学術集会  

乳癌（周術期薬物療法）　教育講演２２　応用編

第17回日本臨床腫瘍学会学術集会  

KEYNOTE-756: randomized, double-blind, phase 3 study of pembrolizumab + neoadjuvant CT + adjuvant ET for ER+/HER2- BC. P2-236

ニボルマブ治療中に免疫性血小板減少性紫斑病を発症し治療に難渋した一例 P2-305

第17回日本臨床腫瘍学会学術集会  

がんチーム医療ワークショップへの期待と課題　　P1-254

第17回日本臨床腫瘍学会学術集会  

東日本大震災前後における福島県の部位別年齢階級別罹患率の動向〜がん検診を行っている5部位について〜（第2報）　　P1-245

第17回日本臨床腫瘍学会学術集会  

HER2陽性EBCをめぐる、ドイツ・日本のガイドラインを読み解く

第27回日本乳癌学会総会  

PI3K-mTOR経路阻害薬はERが陰転化した内分泌療法耐性乳癌細胞株の抗エストロゲン薬の感受性を回復させる

第27回日本乳癌学会総会  

乳がん患者の抱える栄養と運動についての課題 ~ AYA世代を含むライフステージ別の視点から　(AYAがんの医療と支援のあり方研究会 共催シンポジウム 2)

第27回日本乳癌学会総会  

がん免疫療法の時代の到来と、これからの乳癌診療

第27回日本乳癌学会総会  

乳癌におけるクローディン4発現の分子生物学的検討

第27回日本乳癌学会総会  

乳癌においてVEGFはNRP1/ARHGAP17/Cdc42のネット ワークを通じてfilopodia形成を促進しmigrationを誘導する DP-1-65-3

第27回日本乳癌学会総会  

乳がん原発・脳転移巣の遺伝子発現から探る脳転移機序の検討 DP-1-49-10

第27回日本乳癌学会総会  

薬物療法が著効したHR陰性HER2陽性乳癌に対する非切除療法 の有用性に関する単群検証的試験

第27回日本乳癌学会総会  

分子標的治療薬が変えつつある乳癌ホルモン療法の概念

第２０回ホルモンと癌研究会  

A phase III study comparing trastuzumab emtansine with trastuzumab, pertuzumab, and docetaxel in elderly patients with advanced stage HER2-positive breast cancer: (JCOG1607 HERB TEA study)

55th 2019 American Society of Clinical Oncology annual meeting,  

新規抗がん薬のグローバル臨床開発における日本の役割

福島医学会第476回学術研究集会  

乳癌のバイオロジーにおけるCDK4/6阻害薬の位置付け

第19回ホルモンと癌研究会  

院内がん登録を用いた福島県におけるステージIV大腸癌の診療実態調査.

日本がん登録協議会第 27 回学術集会  

院内がん登録データ分析結果から見た当院における胃癌診療の特徴.

日本がん登録協議会第 27 回学術集会  

アロマターゼ阻害薬耐性進行・再発乳癌に対する治療選択

第26回日本乳癌学会総会  

改訂された新ガイドラインの紹介

第26回日本乳癌学会総会  

乳癌におけるClaudin-4高発現の臨床病理学的意義

第26回日本乳癌学会総会  

福島県院内がん登録データの解析

第28回日本疫学会学術総会  

東日本大震災とそれに引き続く福島第一原子力発電所事故前後における福島県及び近隣県でのがん罹患の動向

第28回日本疫学会学術総会  

乳癌に対するホルモン療法の効果予測

第18回関東ホルモンと癌研究会  

Future perspective of oral-FU drug in the management of breast cancer (Luncheon Industry Symposium)

3rd World Congress on Controversies in Breast Cancer  

Satge 0乳癌に対する薬物療法の将来（パネルデイスカッション８）

第55回日本癌治療学会学術集会  

分子標的治療薬が変えた進行再発乳癌の治療戦略（ランチョンセミナー）

第294回　東海外科学会  

がん微小環境免疫応答・ＰＡＲＰ阻害；乳癌薬物療法の新たな波（ランチョンセミナー）

第23回日本家族性腫瘍学会学術集会  

乳癌薬物療法のアップデート（教育講演）

第１5回日本臨床腫瘍学会学術集会  

ホルモン陽性乳がん細胞におけるエストロゲン刺激はHER3分解に関与する

第２5回日本乳癌学会学術総会  

乳癌における原発腫瘍と脳転移腫瘍の免疫微小環境の変化（厳選口演）

第２5回日本乳癌学会学術総会  

ER陽性 HER2 陰性乳癌におけるこれからのトランスレーショナルリサーチ（イブニングセミナー）

第２5回日本乳癌学会学術総会  

From ER to ER, History and future of hormone dependent breast cancer research

International Cancer Research Symposium 2017  

Overcoming endocrine therapy resistance in breast cancer, a cat and mouse game?

真の個別化医療を求めて　Precision Medicineを目指す乳癌薬物療法の過去と未来

第24回日本乳癌学会総会